IPC

Indian Pharmacopoeia Commission

Annual Report
2012-13

CONTENTS

Preface

Standards for drugs are of paramount importance for regulating the Quality, Safety and Efficacy of Drugs used in any country. The Indian Pharmacopoeia (IP) is the official book of standards prescribing standards of identity, purity and strength of drugs to be complied with by drugs imported, manufactured for sale, stocked or exhibited for sale or distributed in India. **IP is the book of standard of the country to be relied upon for quality control of the drugs in India by the regulatory bodies of the Central and States Drugs Control Organizations**. The Pharmacopoeia contributes to the overall control of the quality of medicinal products by providing authentic norms of quality that a product, material or notified medical device is required to meet at any time during its period of use. The Pharmacopoeial Standards, which are publicly available and legally enforceable, are designed to be adopted for the licensing and quality control processes of drugs and are part of the system for safeguarding the health of consumers of medicinal products. The preparation and publication of pharmacopoeia is an exacting task and the rigors involved in preparing the Pharmacopoeia is extremely demanding as the efforts to work out the contents of the monographs of drugs prescribing parameters of quality, efficacy and efficiency are to be prescribed precisely. The field of drugs and pharmaceuticals change at enormous pace not only in the matter of new molecules and dosage forms being introduced but also in the matter of quality control and assurances as newer methods and techniques of identification and determination of purity and impurities are invented and adopted. The I P monographs are therefore to be reviewed and revised periodically to incorporate the changed needs and the I P itself is to be republished periodically incorporating all updates. Addenda are also to be published in between editions to notify and rectify errors if any, in the preceding edition and to incorporate additional monographs on priority basis. The Pharmacopoeial Standards are required to be upgraded regularly as the safety requirements tend to get more and more stringent also. In our country we had not given sufficient attention to streamline the preparation and publication of the Indian Pharmacopoeia, which has often led to criticism about our book of drug standards, its production and distribution and also had resulted in lack of updated national standards. Realizing the facts and also the administrative and scientific matters involved. After independence, the Indian Pharmacopoeia Committee was constituted in 1948, for publication of IP as its main function, which published the IP in 1955, followed by a Supplement in 1960. This Pharmacopoeia contained both western and traditional system drugs commonly used in India, and the same policy continued while preparing the Pharmacopoeia of India 1966 and its Supplement 1975. There had been a phenomenal growth and development of the Indian Pharma industry since independence, especially from early 1970 both in the range of Active Pharmaceutical Ingredients (APIs) and the dosage forms produced. This had totally transformed the profile of the Indian Pharmaceuticals market. Indian Pharma industry had emerged as one of the important global supplier of pharmaceutical products, both to the developed and developing countries. These developments posed major challenges for the IP to reflect the quality standards of the marketed drugs, which the subsequent editions of IP tried to address.

In view of these rapid advances, it was decided to publish a new edition of the Pharmacopoeia and its Addenda at regular and shorter intervals for which the Indian Pharmacopoeia Committee was reconstituted in 1978. In the Pharmacopoeia of India 1985, its Addenda 1989 and 1991, inclusion of traditional system of drugs were limited. However, most of the new drugs manufactured and/or marketed were included, while only those herbal drugs which had definitive quality control standards had got place in it. In view of the continuing rapid increase in the range of drugs produced in India, the IP 1996, its Addendum 2000, Supplement 2000 for Veterinary Products and Addenda 2002 were published. The Addendum 2005 was published by the IPC which included a large number of antiretroviral drugs, and raw plants commonly used in making medicinal products not covered by any other pharmacopoeias and attracted much global attention. The IP Committee decided to delete the obsolete or less used product monographs and added monographs based on the therapeutic merit, medical need and extent of use of such articles in the country.

The Indian Pharmacopoeia Commission has been established in year 2005. It provided systematic approach and practices for publication of IP 2007 with focus on those drugs and formulations that cover the National Health Care Programmes and the National Essential Medicines. It contained monographs on antiretroviral, anticancer, antituberculosis and herbal drugs. It further emphasized on biological monographs such as Vaccines, Immunosera for Human use, Blood products, Biotechnological and Veterinary (Biological and non-biological) preparations. Addendum 2008 to the IP 2007 was published which had taken care of the Amendments to IP 2007 and also incorporated 72 new monographs.

The sixth edition of the Indian Pharmacopoeia (IP 2010) has been published in accordance with the principles and designed plan decided by the Scientific Body of the IPC. To establish transparency in setting standards for this edition, the contents of new monographs, revised appendices and other informations have been publicized on the website of the IPC, besides following conventional approach of obtaining comments. The feedback and inputs were reviewed by the relevant Expert Committee to ensure the feasibility and practicability of the standards and methods revised. The principle of “openness, justice and fairness” is kept in mind during compiling and editing the contents of this edition. The IP 2010 incorporates 1918 monographs of drugs out of which 287 are new monographs consisting of APIs, excipients, dosage forms and herbal products etc. 51 monographs were added in Addendum 2012 to IP 2010.

The work on edition of IP 2014 is under active progress. The manuscript has been prepared extensively examined and found worth to be complying with requirements. It is expected that the ensuring edition of IP 2014 will shortly roll out of the press for the usage and reference of stakeholders. The issue of preparation, certification and distribution of IP Reference Substances has been taken on war footing basis and Commission is ready to release 192 IPRS. The Commission is briskly analysing and validating the Certificate of Analysis (COA) of new drugs assigned to it by CDSCO. The Commission has been accredited by various accreditation bodies.

The Central Government established a full-fledged **Indian Pharmacopoeia Commission (IPC)**, an autonomous society registered under the Society Registration Act, 1860, to carry out the important, complicated and arduous job of preparing and publishing the Indian Pharmacopoeia (IP) periodically. While Indian Pharmacopoeia is a book of standards, the National Formulary of India is a book of reference to be used by medicinal practitioners, pharmacists and nurses. The task of publication of National Formulary of India was also assigned to the IP Commission. The work on the next edition of NFI has been commenced and it has optimized that the ensuring edition will come out shortly.

Introduction

The Drugs & Cosmetics Act, 1940 and Rules, 1945 there under prescribe Standards to be complied with imported drugs and by drugs manufactured for sale, stocked or exhibited for sale or distributed. The Second Schedule of the Act states about standards of identity, purity and strength specified in the edition of the Indian Pharmacopoeia for the time being in force and such other standards as may be prescribed.

Further, the Drugs and Cosmetics Rules, 1945 under its [A] Part - XII which deals with Standards of drugs states.

A. "Standards of drugs" –

For drugs included in the Indian Pharmacopoeia:

(a) The standards for identity, purity and strength shall be those as may be specified in the edition of the Indian Pharmacopoeia for the time being in force.

(b) In case the standards for identity, purity and strength for drugs are not specified in the edition of the Indian Pharmacopoeia for the time being in force but are specified in the edition of the Indian Pharmacopoeia immediately preceding, the standards for identity, purity and strength shall be those occurring in such immediately preceding edition of the Indian Pharmacopoeia.

Drugs & Cosmetics Rule,1945, Rule 96 further specified as;

B. "Manner of Labelling."

Subject to the other provisions of these rules, the following particulars shall be either printed or written in indelible ink and shall appear in a conspicuous manner on the label of the innermost container of any drug and on every other covering in which the container is packed, namely:-

The name of the drug:

For this purpose, the proper name of the drug shall be printed or written in a more conspicuous manner than the trade name, if any, which shall be shown immediately after or under the proper name and shall be –

(a) for drugs included in Schedule F or Schedule F(1), the name given therein;

(b) for drugs included in the Indian Pharmacopoeia or the official pharmacopoeias and official compendia of drug standards prescribed in Rule 124, the name or synonym specified in the respective official pharmacopoeias and official compendia of drug standards followed by the letters 'I.P.' or, as the case may be, by the recognised abbreviations of the respective official pharmacopoeia and official compendia of drug standards;

(c) for drugs included in the National Formulary of India, the name or synonym specified therein followed by the letters 'N.F.I.';

(d) for other drugs, the international non-proprietary name, if any, published by the World Health Organization or where an international non-proprietary name is not published, the name descriptive of the true nature or origin of the substance.

Drugs & Cosmetics Rules, 1945, Rule 104 also clarify about the Use of letters I.P. as;

C. "Use of letters I.P., etc."

The letters 'I.P.' and recognized abbreviations of pharmacopoeias and official compendia of drug standards prescribed under these rules shall be entered on the label of the drug only for the purpose of indicating that the drug is in accordance with standards set out in the Indian Pharmacopoeia or in any such pharmacopoeia or official compendium of drug standards recognized under the Rules.

The Govt. of India have created a separate, dedicated, autonomous institution in the form of the Indian Pharmacopoeia Commission (IPC) to deal with matters relating to timely publication of the Indian Pharmacopoeia which is the official book of standards for drug included therein, in terms of the Second Schedule to the Drugs and Cosmetics Act, 1940 so as to specify the standards of identify, purity and strength of the drugs imported, manufactured for sale, stocked or exhibited for sale or distributed in India. The mandate of the Commission is to perform, *inter-alia*, functions such as revision and publication of the Indian Pharmacopoeia and National formulary of India on a regular basis besides providing Reference Substances for deciding the identity, purity and also detect impurities of drugs and for imparting training to the stakeholders on Pharmacopoeial issues. The Commission has become fully operational from 1st January, 2009 as an Autonomous Body, fully financed by the Central Government with specific budgetary allocations under the administrative control of the Ministry of Health and Family Welfare.

The Indian Pharmacopoeia Commission (IPC) is an unique organisation of the country situated in the National Capital Region just 20 K.M. away from New Delhi. As already stated, it is an autonomous institution under the administrative control of Ministry of Health & Family Welfare, Government of India and dedicated for setting of standards for Drugs, Pharmaceuticals and health care devices/ technologies, publishing the Indian Pharmacopoeia which is the authentic book of standards under the drugs and Cosmetics Act 1940, besides providing references substances and training. The IPC has been registered as a society under the provisions of the Literary, Scientific and Charitable Societies Registration ACT, 1860 (Act No. 21 to 1860) on 9th December 2004. The functioning of the Commission is governed by the provisions of bye-laws of the IPC. The Commission has its Headquarter in its own campus at Sector-23, Raj Nagar, Ghaziabad (U.P.).

The structure of the Commission is as under:

The Commission has a three-tier structure comprising of the General Body, the Governing Body and the Scientific Body, supported by IPC Secretariat and Indian Pharmacopoeial Laboratory. The IPC also provides research and training facilities to students and scientific staff of various pharmacy and biotechnology colleges from different Universities and from other stakeholders. The structure and composition of the bodies are detailed in the report.

The IPC has collaborations with some international institutions and organizations like USP convention, British Pharmacopoeia Commission, European Directorate for the Quality of Medicines and Healthcare (EDQM), Chinese Pharmacopoeia Commission and the World Health Organization. These were partly inherited from the erstwhile CIPL and partly accomplished afresh. The IPC is to regularly update and prepare monographs of drugs of Active Pharmaceutical Ingredients and their formulations.

The IPC intends to publish the Indian Pharmacopoeia once in two years and addendum in between to incorporate corrections, modifications, additions etc. The IPC has a well established and digitalised library and information centre to cater the needs of its staff and other scientific institutions nearby. The Commission subscribes to national and international online journals, which are made accessible for higher studies and research work. The time ahead will be a challenging period for the Commission for completing the works undertaken on time and to embark on new projects. The IPC is making all efforts within its available resources to meet its aims and objectives and to attain its Mission.

To meet expectation of stakeholders, the Commission is working vigoursly and the work is steering satisfactorily to achieve the targets for new edition of IP 2014 where exercises for the 577 new monographs and up-gradation of 1952 monographs have been completed. In this edition, for the first time, 19 new Radiopharmaceutical monographs and one General Chapter is to be included. Emphasis has been laid upon plytopharmaceutical components. Veterinary products have also found space in this ensuring edition Classical chemical tests have been eliminated with that of internationally acclaimed UV spectrophotometric tests.

Work on NFI's 5th edition is also accelerating in top slot and it is hoped that the 5th edition of NFI will be serving the cause of physicians, nurses and pharmacists in particular and common masses in general. The principle of 'openness, justice and fairness is kept into consideration while editing /compiling the ensuring edition of NFI and IP. These editions are the outcome of valuable contribution of the members of the expert committees of Scientific Body, professionals of the industry, the public and private testing laboratories and employees of the IPC.

The day is not far when the state-of-the art laboratory will start functioning in the very campus of the Commission under the able guidance, blessings and support of Ministry's officers.

From the Secretary-cum-Scientific Director's Desk

I am immensely delighted to present the fifth annual progress report before yourselves. The financial year under annual report was very challenging for the Commission as far as the question of publication of Indian Pharmacopoeia 2014 edition was concerned and the Commission has come out successfully through hard waters on account of less number of working hands and limited number of high end instruments when the credibility at international level is questioned in terms of quality, efficacy and standardization of drugs. It is pertinent to note that not only Commission prepared manuscript in time but also added 577 new monographs. It gives me satisfying note that our scientists are working day and night and are on verge of adding 19 new monographs on Radiopharmaceuticals along with one General Chapter. The Commission not satiated itself to the timely publication of Pharmacopoeia, the book of standards but also working vigorously on the book of reference called National Formulary of India 5th edition. The onus of this performance goes to the principles of transparency, accountability and punctuality adopted by the Commission willingly. The Commission is working towards rational use of medicines through generic approach. In this direction, the Commission is in the process of certifying, preparing and manufacturing Indian Pharmacopoeia Reference substances and till now most essentially required (300) IP Chemical Reference substances have been certified. The National Coordination Centre of Pharmacovigilance Programme of India (PvPI) has recommended ban on 5 drugs to CDSCO on the basis of ADR received from monitoring centres based in 90 Medical Colleges/Hospitals of the nation.

The journey of the IPC seems to be more challenging in the times ahead as it has to provide highly updated and upgraded infrastructure facilities needed for executing the responsibilities vested with it and to meet the international and national standards expected out of such an institution. State of the art infrastructural facilities, human resources and creating congenial environment for delivering the services as done by other Standards Setting institutions globally are priority needs. The IPC intends to become role model in times to come for its quality services and humility of approach by way of cooperation, coordination and involvement of it's stakeholders.

The guidance and approach extended by the Ministry and cooperation provided by the members of Scientific Body and other expert members alongwith the staff of the IP Commission are highly praiseworthy. I would like to extend my deep sense of gratitude to all those who guided during the period and to the Government for the unfettered support provided to the IP Commission to achieve its targets.

With best wishes.

Dr.G.N.Singh

MISSION, VISION AND OBJECTIVES



Fig: 2-Functions of IPC

Mission: To protect and promote public health by bringing out authoritative and officially accepted standards for quality of drugs including active pharmaceutical ingredients, excipients, dosage forms and medical devices for use by health professionals, patients and consumers.

Vision: To promote the highest standards for drugs for use in humans and animals within practical limits of the technologies available for manufacture and analysis.

Objectives: To develop comprehensive monographs for drugs to be included in the Indian Pharmacopoeia, including active pharmaceutical ingredients, excipients and dosage forms as well as medical devices, and to keep them updated by reviews and revisions on a regular basis.

- To accord priority to monographs of drugs included in the national Essential Drugs List and their dosage forms.
- To prepare monographs for products that have normally been in the market for not less than 2 years except for certain special categories of new drugs like antiretrovirals, antituberculosis and anticancer drugs and their formulations introduced more recently needing priority attention.
- To give special attention to the methods of manufacture used by the indigenous industry in selecting the pharmacopoeial tests for monitoring the toxic impurities as applicable to such drugs.
- To take note of the different levels of sophistication in analytical testing/instrumentation available while framing the monographs.

- To accelerate the processes of preparation, certification and distribution of IP Reference Substances, including the related substances, impurities and degradation products required.

- To collaborate with other pharmacopoeia commissions like the Ph Eur, BP, USP, JP, ChP and International Pharmacopoeia with a view to harmonizing the national standards with global standards without harming the National interests and concerns.

- To organize educational programs and research activities for spreading and establishing awareness on the need and scope of quality standards for drugs and related articles/ materials.

Composition of the Indian Pharmacopoeia Commission



Fig.-1 Structure of IPC

Bodies of the IPC:

The composition of the **Governing Body** is given below:

S. No.	*Designation in Committee*	Name & Address
1.	*Chairman*	Shri Keshav Desiraju Secretary (Health & Family Welfare) Government of India Ministry of Health & Family Welfare Nirman Bhawan New Delhi-110 011.
2.	*Co-Chairman*	Prof. B. Suresh Vice-Chancellor, J. S. S. University, JSS Medical Institution Campus, Sri Shivarathreeshwara Nagara, Mysore-570 015
3.	*Member*	Shri R. K. Jain, Additional Secretary & Director General (CGHS) Ministry of Health & Family Welfare Nirman Bhawan New Delhi-110 011.
4.	*Member*	Shri S. K. Srivastava Additional Secretary & Finance Advisor Ministry of Health & Family Welfare Nirman Bhawan New Delhi -110 011.
5.	*Member*	Dr. Arun Kumar Panda Joint Secretary (R) Ministry of Health & Family Welfare, Nirman Bhawan New Delhi-110 011.
6.	*Member*	Dr. G. N. Singh Drugs Controller General (I), Directorate General of Health Services Ministry of Health & Family Welfare FDA Bhawan, Kotla Road, New Delhi.
7.	*Member*	Shri Shailendra Kumar Director (Drugs) Ministry of Health & Family Welfare Nirman Bhawan New Delhi-110 011
8.	*Member*	Dr. Surinder Singh Director National Institute of Biologicals B-62, Institutional Area Noida-201 307

9.	*Member*	Shri Shambhu Kallolikar Joint Secretary Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers Shastri Bhawan, New Delhi
10.	*Member*	President, Pharmacy Council of India, Combined Councils' Building, Kotla Road, Aiwan-E-Ghalib Marg, Post Box No. 7020 New Delhi-110 002
11.	*Member*	Professor (Dr.) Lalji Singh, Vice-Chancellor, Banaras Hindu University, Varanasi -221 005 (U.P).
12.	*Member*	Dr. Kiran Mazumdar Shaw C&MD, Biocon Ltd., 20th KM, Hosur Road, Electronics City Bangalore- 560 100
13.	*Member-Secretary*	Dr. G. N. Singh Secretary-cum-Scientific Director Indian Pharmacopoeia Commission Sector-23, Rajnagar Ghaziabad-201 002

The composition of the **General Body** is as follows:

S. No.	***Designation in Committee***	**Name & Address**
1.	*Chairman*	Shri Keshav Desiraju Secretary (Health & Family Welfare) Government of India Ministry of Health & Family Welfare Nirman Bhawan New Delhi-110 011.
2.	*Co-Chairman*	Prof. B. Suresh Vice-Chancellor, J. S. S. University, JSS Medical Institution Campus, Sri Shivarathreeshwara Nagara, Mysore-570 015
3.	*Member*	Shri R. K. Jain, Additional Secretary & Director General (CGHS) Ministry of Health & Family Welfare Nirman Bhawan New Delhi-110 011.
4.	*Member*	Shri S. K. Srivastava Additional Secretary & Finance Advisor Ministry of Health & Family Welfare Nirman Bhawan New Delhi -110 011.
5.	*Member*	Dr. Arun Kumar Panda Joint Secretary (R) Ministry of Health & Family Welfare, Nirman Bhawan New Delhi-110 011.
6.	*Member*	Dr. G. N. Singh Drugs Controller General (I), Directorate General of Health Services Ministry of Health & Family Welfare FDA Bhawan, Kotla Road, New Delhi.
7.	*Member*	Shri Shailendra Kumar Director (Drugs) Ministry of Health & Family Welfare Nirman Bhawan New Delhi-110 011
8.	*Member*	Dr. Surinder Singh Director National Institute of Biologicals B-62, Institutional Area Noida-201 307

9.	*Member*	Shri Shambhu Kallolikar Joint Secretary Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers Shastri Bhawan, New Delhi
10.	*Member*	President, Pharmacy Council of India, Combined Councils' Building, Kotla Road, Aiwan-E-Ghalib Marg, Post Box No. 7020 New Delhi-110 002
11.	*Member*	Professor (Dr.) Lalji Singh, Vice-Chancellor, Banaras Hindu University, Varanasi -221 005 (U.P).
12.	*Member*	The Director Central Drugs Laboratory 3, Kyd Street Kolkata
13.	*Member*	From Regulatory Bodies Central Drugs Standard Control Organisation Directorate General of Health Services, FDA Bhawan, Kotla Road, New Delhi.
14.	*Member*	Dr. C. Adithan Director-Professor Department of Pharmacology Jawaharlal Institute of Postgraduate Medical Education and Research Pondicherry-605 006.
15.	*Member*	Commissioner in-charge of Drug Control Administration, Andhra Pradesh
16.	*Member*	Commissioner in-charge of Drug Control Administration, Sikkim
17.	*Member*	Commissioners in-charge of Drug Control Administration, Gujarat
18.	*Member*	Commissioner in-charge of Drug Control Administration, Uttar Pradesh

19.	*Member*	Commissioner in-charge of Drug Control Administration, Himachal Pradesh
20.	*Member*	The Director National Institute of Pharmaceutical Education and Research (NIPER) Sector 67, SAS Nagar Mohali-160 062.
21.	*Member*	The President, Indian Drug Manufacturers Association (IDMA) 102-B, Poonam Chambers, 'A' Wing' Dr. Annie Besant Road, Worli Mumbai – 400018
22.	*Member*	The President, Organization of Pharmaceutical Producers of India (OPPI), Peninsula Corporate Park, Peninsula Chambers, Gr. Floor, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013
23.	*Member*	Shri. D. G. Shah, Secretary General, Indian Pharmaceutical Alliance (IPA), Mumbai
24.	*Member*	Dr. Kiran Mazumdar Shaw C&MD, Biocon Ltd., 20th KM, Hosur Road, Electronics City Bangalore- 560 100
25.	*Member-Secretary*	Dr. G. N. Singh Secretary-cum-Scientific Director Indian Pharmacopoeia Commission Sector-23, Rajnagar Ghaziabad-201 002

The composition of the **Executive Committee** is as follows:

S. No.	**Designation in Committee**	**Name & Address**
1.	*Chairman*	Prof. B. Suresh Vice-Chancellor, J. S. S. University, JSS Medical Institution Campus, Sri Shivarathreeshwara Nagara, Mysore-570 015
2.	*Member*	Drugs Controller General (I) Dte. General of Health Services, FDA Bhawan, Kotla Road, New Delhi.
3.	*Member*	Professor (Dr.) Lalji Singh, Vice-Chancellor, Banaras Hindu University, Varanasi -221 005 (U.P).
4.	*Member-Secretary*	Dr. G. N. Singh Secretary-cum-Scientific Director Indian Pharmacopoeia Commission Sector-23, Rajnagar Ghaziabad-201 002

The composition of the **Scientific Body** is as follows:

S. No.	**Designation in Committee**	**Name & Address**
1.	*Chairman*	Prof. B. Suresh Vice-Chancellor, J. S. S. University, JSS Medical Institution Campus, Sri Shivarathreeshwara Nagara, Mysore-570 015
2.	*Member*	Dr. G. N. Qazi Vice Chancellor, Jamia Hamdard Hamdard University, 'A' Category – NAAC, Hamdard Nagar, New Delhi-110 062.
3.	*Member*	Dr. N. Udupa Principal, Manipal College of Pharmaceutical Sciences, Madhav Nagar, Manipal-576 104. Karnataka
4.	*Member*	Professor M. R. Yadav Pharmacy Department, Faculty of Technology and Engineering, The M. S. University of Baroda, Vadodara– 390 001 (Gujarat)
5.	*Member*	Dr. B. Sesikeran Director, National Institute of Nutrition, Jamai-Osmania Post Office, Tarnaka Road, Hyderabad, Andhra Pradesh 500 007.
6.	*Member*	Dr. D. B. Anantha Narayana Former Director, Hindustan Lever Research Centre, #15 (Old No 1101/927), 1 "F" Main Road, 2nd Stage, Giri Nagar, Bangalore - 560085
7.	*Member*	Professor Praveen Aggarwal, Professor in-charge, Department of Emergency Medicine,

		All India Institute of Medical Sciences (AIIMS), Ansari Nagar, New Delhi-110 029.
8.	*Member*	Professor Y. K. Gupta Head, Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Ansari Nagar, New Delhi.
9.	*Member*	Professor (Dr.) Lalji Singh Vice-Chancellor, Banaras Hindu University, Varanasi -221 005 (U.P) India
10.	*Member*	Dr. S. M. Mudda Executive Director – Technical & Operations, Micro Labs Limited, 27, Race Course Road, Bangalore-560 001.
11.	*Member*	Dr. Manish Gangrade Head-Analytical Development Lab, CIPLA Limited, L.B.S. Marg, Vikhroli (W), Mumbai-400 083.
12.	*Member*	Dr. J. P. Mehta Plant Manager, Franco-Indian Pharmaceuticals Pvt. Ltd., 20, Dr.E. Moses Road, Worli, Mumbai-400 011.
13.	*Member*	Dr. Vinay G. Nayak President Technical Operations International Business Division Alembic Ltd, Alembic Road, Vadodara – 390003
14.	*Member*	Mr. Vinod Arora Vice President (Pharma Research), Ranbaxy Research Laboratories, Plot No. 20, Sector 18, Udyog Vihar Industrial Area, Gurgaon-122 001.
15.	*Member*	Dr. S. S. Jadhav Executive Director, Quality Assurance & Regulatory Affairs, Serum Institute of India Ltd.,

		212/2, Hadapsar, Pune-411 028.
16.	*Member*	Prof. Rakesh Kumar Sharma Additional Director and Head, CBRN Defence Institute of Nuclear Medicine and Allied Sciences (INMAS), Brig SK Mazumdar Marg, Delhi 110 054 INDIA
17.	*Member*	Dr. Patel Bharatkumar Natubhai Joint Commissioner (Testing), Food & Drugs Laboratory, Nr. Polytechnic, Baroda – 390 002 (Gujarat)
18.	*Member*	Dr. S. Y. Pandey Director, Chemistry and Business Development, Jai Research Foundation, Daman Ganga Bridge, N.H. No. 8, Valvada - 396 108 , Dist. Valsad, Gujarat.
19.	*Member*	Dr. H. G. Koshia Commissioner, Food & Drugs Control Administration Government of Gujarat, Block No. 8, 1st Floor, Dr. Jivraj Mehta Bhavan, Gandhinagar-382 010.
20	*Member*	Dr. Prasad V. Kanitkar Director, Plant Operations, Pfizer Global Manufacturing, Pfizer Limited, Thane Belapur Road, K.U. Bazar Post, Turbhe, Navi Mumbai-400 705.
21.	*Member*	Dr. Anurag Rathore, Associate Professor, Department of Chemical Engineering, Indian Institute of Technology, Hauz Khas, New Delhi-110 016.
22.	*Member*	Mr. R. Sridharan 603, Sarangi, Lokpuram, Thane (W) – 400 610
23.	*Member-Secretary (ex-officio)*	Dr. G. N. Singh Secretary-cum-Scientific Director Indian Pharmacopoeia Commission

		Sector-23, Rajnagar Ghaziabad-201 002

The composition of the **National Consultative Committee (NCC)** of **the Indian Pharmacopoeia Commission** is as follows:

S. No.	**Designation in Committee**	**Name & Address**
1.	*Chairman*	Dr. Vishwa Mohan Katoch, Secretary to the Govt. of India (DHR), and Director General, Indian Council of Medical Research, Ramalingaswamy Bhawan, Ansari Nagar, New Delhi-110 029.
2.	*Co-Chairman*	*Mr. R. K. Jain* *Additional Secretary & Director General (CGHS)* *Ministry of Health & Family Welfare* *Nirman Bhawan* *New Delhi-110 011.*
3.	*Member*	Dr. Surinder Singh Director (I/C), National Institute of Biologicals B-62, Institutional Area Noida-201 307
4.	*Member*	Professor (Dr.) Lalji Singh Vice-Chancellor, Banaras Hindu University, Varanasi -221 005 (U.P) India
5.	*Member*	Prof. B. Suresh Vice-Chancellor, J. S. S. University, JSS Medical Institution Campus, Sri Shivarathreeshwara Nagara, Mysore-570 015
6.	*Member*	Professor C. K. Kokate Vice-Chancellor KLE University Belgaum
7.	*Member*	Dr. G. N. Qazi Vice-Chancellor, Jamia Hamdard Hamdard University, 'A' Category – NAAC, Hamdard Nagar, New Delhi-110 062.

8.	*Member*	Professor Y. K. Gupta Head, Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Ansari Nagar, New Delhi.
9.	*Member*	Dr. P. V. Appaji Executive Director Pharmaceuticals Export Promotion Council (Pharmexcil) 101, Aditya Trade Centre, Ameerpet, Hyderabad-500 038.
10.	*Member*	Mr. M. Ayyapan C&MD HLL Mahilamandiram Road Poojappura Thiruvananthapuram-695 1012.
11.	*Member*	Drugs Controller General (I) (I/C), Directorate General of Health Services Ministry of Health & Family Welfare FDA Bhawan, Kotla Road, New Delhi.
12.	*Member*	Dr. B.E. Rao WHO Consultant and Ex-CMD, IDPL 906, Amsri, Central Court (Old Lancer Road) Secunderabad- 500 025.
13.	*Member*	Dr. M. Bamji Former Director Grade Scientist National Institute of Nutrition 211 Sri Datta Sai Apartments RTC Cross Road Hyderabad-500 020.
14.	*Member*	Mr. Pankaj Patel C&MD Cadila Health Care Zydus Tower Satellite Cross Road Ahmedabad- 380 015.

15.	*Member*	Dr. Sudershan Arora President, Ranbaxy Research Laboratory Plot No. 20, Sector 18 Udyog Vihar Gurgaon.
16.	*Member-Secretary*	Dr. G. N. Singh Secretary-cum-Scientific Director Indian Pharmacopoeia Commission Sector-23, Rajnagar Ghaziabad-201 002

Expert Working Groups

Review of IP Work
Mr. J.L. Sipahimalani (*Chair*), Mr. R. Raghunandanan, Mr. R. Sridharan.

Anti-Cancer
Dr. K.V. Jogi (*Chair*), Dr. B. Nagaraju, Dr. N. Padmaja, Mr. Mohan jain.

Anti-Retroviral
Dr. Manish Gangrade (*Chair*), Dr. Antony Raj Gomes, Ms. Rashmi Srivastava, Dr. Suryanarayana Muluktla.

Radiopharmaceuticals
Dr. Rakesh Kumar Sharma *(Chair),* Dr. M.G..R. Rajan, Dr. N.C. Goomer, Dr. N. Shivaprasad, Dr. Aruna Korde, Dr. Sanyog Jain.

Biologics
Dr. Surinder Singh (*Chair*), Dr. Anurag Rathore, Dr. S.S. Jadhav.

Excipients
Dr. P.V. Kanitkar (*Chair*), Mr. Subodh Priolkar, Dr. D.B.A. Narayana, Dr. Shailesh Nagarsenkar.

General Chapters
Dr. V.G. Nayak (*Chair*), Dr. Sunil Nadkrani, Mr. Antony R. Gomes, Dr. Vinay Aroskar, Dr. Pramod Dalvi, Dr. Sunder Kalyana Balaji, Mr. Kundan D. Patil, Mr. Deepak Jakate, Mr. Sanjay Deshpandey, Dr. V. B. Malkar, Mr. Mohan Jain, Dr. Luis Countinho.

General Chapters on Dosage forms
Mr. Vinod Arora (*Chair*), Dr. Prashant Dixit.

Herbal Products
Dr. D.B.A. Narayana (*Chair*), Dr. Amit Agrawal, Dr. G. Patani, Dr. Pulok Mukherjee, Dr, M.N. Nanjan, Dr. C.K. Katiyar.
Sub-group on Essential Oils
Dr. Ramakant Harialkha, Mr. B. Murali, Dr. Rahul Singh, Ms. Bhuvana Nageswaran, Dr. Hema Lohani.

Inhalation Products
Mr. R. Sridharan (*Chair*), Mr. Satish Sharma, Mr. Sanjay Gupta, Mr. Nagesh Shenoy, Mr. Ganadish Kamat/ Amit Sule, Mr. S.G. Belapure.

Medical Devices
Dr. Ishwar Reddy (*Chair*).

Microbiology- General
Dr. J.P. Mehta (*Chair*), Dr. Gopa Ghosh, Mr. S.N. Chavan, Dr. Jadhav, Mr. A.P. Mohan, Dr. P. K. Chitnis, Mr. Ashok Desai.

Opthalmics
Dr. S.M. Mudda (*Chair*), Mr. V. Shiv Kumar, Ms. Shakila S. Pai, Mr. R.T. Arasu, Mr. Navneet V. Mehta, Ms. S. Asha, Mr. P. Venkata Reddy, Ms Aditi Panandikar.

Parenteral Preparation- General
Mr. Satish R. Kulkarni (*Chair*), Mr. Hemal Patel, Mr. Vijay V. Kshirsagar, Mr. H.T. Nazare, Mr. S.L. Jat, Mr. Sudhir Pandya.

Veterinary Products
Mr. Rishendra Verma (*Chair*), Dr. V.A. Srinivasan.

Vaccines
Mr. S.S. Jadhav (*Chair*), Dr. Arun Bhardwaj, Dr. V.A. Srinivasan, Dr. Sumant Sharachchandra Karnik, Dr. Sunil Gairola, Dr. Mahesh Bhalgat, Mr. Anil Sood, Mr. P.M. Patel, Mr. Parag P. Nagarkar, Dr. K. Anand Kumar.

Biological and rDNA Products
Dr. Anurag Rathore (*Chair*)**,** Mr. S.S. Jadhav, Dr. Venkata Ramana, Dr. Anil Kukreja, Dr. Sriram Akundi, Dr. Jaideep Moitra, Mrs. Kinnari Vyas, Mr. Arvind Kukreti, Dr. Renu Jain, Dr. Sanjeev Kumar, Dr. Rahul Kulkarni, Dr. Himanshu Gadgil, Dr. Satyanarayana Subrahmanyam.

Website
Dr. D.B.A. Narayana (*Chair*), Dr. Venugopal, Mr. G..S. Bedi.

Scientific Activities & Achievements

1. New Monographs Drafted for next VIIth edition of IP

Following 315 new chemical monographs were drafted during this period for next edition and put up on the website for stakeholders comments.

1 Acamprosate Calcium
2 Acesulfame Potassium
3 Acetretin Capsules
4 Aciclovir Cream
5 Aciclovir Dispersible Tablets
6 Aciclovir Eye ointment
7 Aciclovir Oral suspension
8 Acitretin
9 Adefovir dipivoxil
10 Adefovir Tablets
11 Adenosine
12 Adenosine Injection
13 Adipic Acid
14 Albendazole Oral Suspension
15 Alfacalcidol
16 Alfacyclodextrin
17 Alfuzosin Hydrochloride
18 Alfuzosin Prolonged-release Tablets
19 Alfuzosin Tablets
20 Alprazolam Prolonged-release Tablets
21 Alprostadil
22 Alprostadil Injection
23 Aminophylline Prolonged-release Tablets
24 Amiodarone Intravenous Infusion
25 Amisulpride
26 Amisulpride Tablets
27 Amorolfine Hydrochloride
28 Aprotinin
29 Aripiprazole
30 Ascorbyl Palmitate
31 Aspirin Gastro-resistant Tablets
32 Atomoxetine Hydrochloride
33 Atracurium Besylate Injection
34 Atracurium Besylate
35 Azelaic acid
36 Azelastine Eye Drop
37 Azelastine Hydrochloride
38 Bambuterol Hydrochloride
39 Bambuterol Tablets
40 Benazepril Hydrochloride
41 Benazepril Hydrochloride Tablets
42 Benzoyl Peroxide Cream
43 Benzoyl Peroxide Gel

44 Betacyclodextrin
45 Betahistine Mesilate
46 Betamethasone Valerate cream
47 Betaxolol Eye Drops
48 Betaxolol Hydrochloride
49 Bezafibrate
50 Bezafibrate Tablets
51 Bicalutamide
52 Bicalutamide Tablets
53 Bortezomib
54 Cabergoline
55 Cabergoline Tablets
56 Caffeine Citrate Oral Solution
57 Calcipotriol Anhydrous
58 Calcipotriol Ointment
59 Calcitonin (Salmon)
60 Calcitonin (Salmon) Injection
61 Calcium Dobesilate Monohydrate
62 Carboplatin
63 Carboplatin Injection
64 Carboxymethylcellulose Calcium
65 Carboxymethylcellulose Eye Drops
66 Carisoprodol
67 Carisoprodol Tablets
68 Cefpirome Injection
69 Cefpirome Sulphate
70 Ceftiofur sodium
71 Celiprolol Hydrochloride
72 Celiprolol Tablets
73 Chloramphenicol Ear Drops
74 Chlorohexidine Mouthwash
75 Cilostazol
76 Cilostazol Tablets
77 Citicoline Sodium
78 Clemastine Fumarate
79 Clemastine Tablets
80 Clindamycin Injection
81 Clindamycin Phosphate
82 Clobetasol Cream
83 Clobetasol Ointment
84 Clobetasol Propionate
85 Clobetasone Butyrate
86 Clobetasone Cream
87 Colistimethate Injection
88 Colistimethate Sodium
89 Corn Oil
90 Cottonseed oil
91 Crotamiton
92 Crotamiton Cream
93 Cyclopentolate Eye Drops
94 Cyclopentolate Hydrochloride
95 Cyclosporine

96 Cyclosporine Capsules
97 Dalteparin Sodium
98 Dalteparin Sodium Injection
99 Desmopressin
100 Desmopressin Intranasal Solution
101 Diclofenac Prolonged-release Tablets
102 Diltiazem Injection
103 Dipivefrine Eye drops
104 Dipivefrine Hydrochloride
105 Dipyridamole
106 Dipyridamole Tablets
107 Divalproex Prolonged-release Tablets
108 Dobutamine Hydrochloride
109 Dobutamine Injection
110 Docetaxel Anhydrous
111 Domperidone Suspension
112 Dopamine Hydrochloride
113 Dopamine Injection
114 Doxapram Hydrochloride
115 Doxapram Injection
116 Drotaverine Tablets
117 Dutasteride
118 Ebastine
119 Eberconazole nitrate
120 Entacapone
121 Ephedrine Nasal Drops
122 Epinastine Eye Drops
123 Epinastine Hydrochloride
124 Eplerenone
125 Eptifibatide
126 Eptifibatide Injection
127 Erlotinib Hydrochloride
128 Erlotinib Tablets
129 Esmolol Hydrochloride
130 Ethambutol Injection
131 Ethanolamine
132 Ethophylline and TheophyllineTablets
133 Ethyl Vanillin
134 Ethylparaben
135 Etidronate Disodium
136 Etidronate Tablets
137 Etoricoxib
138 Etoricoxib Tablets
139 Ezetimibe
140 Ezetimibe Tablets
141 Famciclovir
142 Famciclovir Tablets
143 Flavoxate Hydrochloride
144 Flavoxate Tablets
145 Flucloxacillin Capsules
146 Flucloxacillin Oral solution
147 Flucloxacillin Sodium

148 Fludarabine Phosphate
149 Fludarabine Phosphate Injection
150 Flumazenil
151 Flumazenil Injection
152 Fluorometholone
153 Fluorometholone Eye Drops
154 Flupentixol Decanoate
155 Flupentixol Injection
156 Flurazepam Capsules
157 Flurazepam Hydrochloride
158 Flurbiprofen Eye Drops
159 Flurbiprofen Sodium
160 Flutamide Tablets
161 Fluticasone Cream
162 Fluticasone Nasal Spray
163 Fluticasone Ointment
164 Fluvastatin Capsules
165 Fluvastatin Sodium
166 Fluvoxamine Maleate
167 Fluvoxamine Tablets
168 Fosinopril Sodium
169 Fosinopril Sodium Tablets
170 Gemcitabine Hydrochloride
171 Gemcitabine Injection
172 Gemfibrozil
173 Gemfibrozil Capsules
174 Glutaraldehyde Solution
175 Glycerin Oral Solution
176 Hydrocortisone Ointment
177 Hydrocortisone Acetate Cream
178 Hydrogenated Vegetable Oil
179 Hydroxychloroquine Sulphate
180 Hydroxychloroquine Tablets
181 Hydroxyethylcellulose
182 Hydroxypropyl Methylcellulose Phthalate
183 Hydroxyzine Hydrochloride
184 Hydroxyzine Oral Solution
185 Hydroxyzine Tablets
186 Imatinib Tablets
187 Imidurea
188 Invert Syrup
189 Iopanoic Acid
190 Iopanoic Acid Tablets
191 Irbesartan
192 Irbesartan and Hydrochlorothiazide Tablets
193 Irbesartan Tablets
194 Iron and Folic Acid Syrup
195 Iron and Folic Acid Tablets
196 Isopropyl Palmitate
197 Isopropyl Rubbing Alcohol
198 Isotretinoin
199 Ivermectin

200 Ivermectin Injection
201 Labetalol Injection
202 Lamivudine, Nevirapine and Zidovudine Paediatric Dispersible Tablets
203 Lapatinib Ditosylate
204 Lapatinib Tablets
205 Leflunomide
206 Leflunomide Tablets
207 Levodropropizine
208 Levofloxacin Injection
209 Levosalbutamol Hydrochloride
210 Levosalbutamol Inhalation Solution
211 Lithium Carbonate Prolonged-release Tablets
212 Lorazepam
213 Lorazepam Injection
214 Lorazepam Tablets
215 Meloxicam
216 Mesalazine
217 Mesalazine Prolonged-release Tablets
218 Metoprolol Injection
219 Midazolam
220 Midazolam Injection
221 Midazolam Oral Solution
222 Mifepristone
223 Mifepristone Tablets
224 Misoprostol Tablets
225 Mitomycin
226 Mitomycin Injection
227 Monobasic Sodium Phosphate
228 Morphine Tablets
229 Moxifloxacin Eye Drops
230 Moxifloxacin Hydrochloride
231 Mupirocin
232 Mupirocin Ointment
233 Nicorandil
234 Nicorandil Prolonged-release Tablets
235 Nicorandil Tablets
236 Octyl dodecanol
237 Ofloxacin Oral Suspension
238 Ornidazole Injection
239 Oxacillin Capsules
240 Oxacillin Sodium
241 Ozagrel Hydrochloride
242 Paracetamol Infusion
243 Paracetamol Paediatric Oral Suspension
244 Parecoxib Sodium
245 Paroxetine hydrochloride
246 Paroxetine Tablets
247 Petrolatum
248 Phenylethyl Alcohol
249 Phenyramidol Hydrochloride
250 Phenyramidol Tablets
251 Pitavastatin Calcium

252 Polacrilin Potassium
253 Polyvinyl Acetate Phthalate
254 Polyvinyl Alcohol
255 Potassium Chloride for Injection
256 Prednisolone Sodium Phosphate Eye Drops
257 Premetrexed Disodium
258 Procarbazine Hydrochloride
259 Progesterone
260 Progesterone Injection
261 Propyliodone
262 Propyliodone Injectable Oil Suspension
263 Pyridostigmine Bromide
264 Pyridostigmine Injection
265 Pyridostigmine Tablets
266 Racecadotril
267 Racecadotril Capsules
268 Racecadotril Sachet
269 Raloxifene Hydrochloride
270 Rebamipide
271 Reboxetine Methanesulphonate
272 Repaglinide
273 Repaglinide Tablets
274 Risendronate Sodium
275 Ritodrine Hydrochloride
276 Ritodrine Injection
277 Ritodrine Tablets
278 Rupatidine Fumarate
279 Saquinavir Capsules
280 Selegiline Hydrochloride
281 Selegiline Tablets
282 Sertraline Hydrochloride
283 Sertraline Tablets
284 Silver Sulphadiazine
285 Silver Sulphadiazine Cream
286 Sodium Nitoprusside
287 Sodium Nitroprusside injection
288 Sodium Valproate Gastro-resistant Tablets
289 Sorafenib Tablets
290 Sorafenib Tosylate
291 Soyabean Oil
292 Strong Glutaraldehyde Solution
293 Sulpride
294 Sulpride Tablets
295 Surgical Spirit
296 Tenofovir fumarate, lamivudine and efavirenz tablets
297 Theophylline Prolonged-release Tablets
298 Tranexamic Acid
299 Tranexamic Acid Injection
300 Tranexamic Acid Tablets
301 Triclofos Oral Solution
302 Triclofos Sodium
303 Ursodeoxycholic Acid

304 Ursodeoxycholic Acid Tablets
305 Vecuronium Bromide
306 Vecuronium Bromide Injection
307 Voglibose
308 Voglibose Dispersible Tablets
309 Zonisamide
310 Zopiclone
311 Zopiclone Tablets
312 Zuclopenthixol Acetate
313 Zuclopenthixol Acetate Injection
314 Terfenadine Oral Suspension
315 Terfenadine Tablets

2. Revision/Upgradation of existing monographs for VIIth edition of IP.

The following monographs were revised/ upgraded for next VIIth edition of IP in respect of different tests like Assay, Related substances etc.

1 Amikacin
2 Amikacin Injection
3 Amikacin Sulphate
4 Amiodarone Hydrohcloride
5 Amiodarone Tablets
6 Ampicillin Trihydrate
7 Aspirin
8 Azithromycin
9 Azithromycin Tablets
10 Bupivacaine Hydrochloride
11 Bupivacaine Injection
12 Butylparaben
13 Caffeine
14 Cefuroxime Axetil
15 Chloroquine Phosphate
16 Chloroquine Phosphate tablets
17 Cholecalciferol Tablets
18 Clarithromycin
19 Clofazimine
20 Clofazimine Capsules
21 Clonidine Hydrochloride
22 Clotrimazole
23 Cloxacillin Sodium
24 Codeine Phosphate
25 Colchicine Tablets
26 Cyclizine Hydrochloride
27 Cyclophosphamide Injection
28 Diazepam

29 Digoxin
30 Diphenhydramine Hydrochloride
31 Dithranol
32 Docetaxel Injection
33 Donepezil Tablets
34 Doxepin Hydrochloride
35 Econazole Nitrate
36 Etoposide
37 Finasteride Tablets
38 Fluphenazine Decanoate
39 Fluphenazine Decanoate Injection
40 Fluphenazine Hydrochloride
41 Fumaric Acid
42 Haloperidol
43 Homatropine Hydrobromide
44 Hydrochlorothiazide
45 HydrochlorothiazideTablets
46 Hyoscine Butylbromide
47 Hyoscine Hydrobromide
48 Hyoscine Hydrobromide Injection
49 Hyoscine Hydrobromide Tablets
50 Ipratropium Bromide
51 Isoprenaline Hydrochloride
52 Isoprenaline Injection
53 Lamivudine
54 Lamivudine , Nevirapine and Stavudine Dispersible Tablets
55 Lamivudine and Zidovudine Tablets
56 Lamotrigine Prolonged-release Tablets
57 Levamisole Hydrochloride
58 Levodopa
59 Levofloxacin Hemihydrate
60 Levonorgestrel Tablets
61 Lignocaine and Adrenaline Injection
62 Mepyramine Maleate
63 Methadone Hydrochloride
64 Methotrexate
65 Methotrexate Injection
66 Methotrexate Tablets
67 Methylergometrine Maleate
68 Methylparaben
69 Mexiletine Hydrochloride
70 Mianserin Hydrochloride
71 Montelukast Sodium
72 Nicotinic Acid

73 Nitrazepam
74 Nortriptyline Hydrochloride
75 Ondansetron Oral Solution
76 Ondansteron Tablets
77 Orphenadrine Citrate
78 Orphenadrine Hydrochloride
79 Perphenazine
80 Phenobarbitone
81 Phentolamine Injection
82 Phentolamine Mesylate
83 Phenylephrine Hydrochloride
84 Phenytoin
85 Phenytoin Sodium
86 Pholcodine
87 Pilocarpine Nitrate
88 Pregabalin
89 Primaquine Tablets
90 Propylparaben
91 Pyridoxine Hydrochloride
92 Ramipril and Hydrochlorothiazide Tablets
93 Ranitidine Hydrochloride
94 Ribavirin
95 Salbutamol Syrup
96 Salicylic Acid
97 Salmeterol Xinafoate
98 S-amlodipine Besylate
99 Sodium Methylparaben
100 Sodium Propylparaben
101 Sodium Stibogluconate
102 Terbutaline Tablets
103 Thiotepa Injection
104 Thyroxine Tablets
105 Timolol Maleate
106 Tolbutamide
107 Tolnaftate
108 Travoprost Eye Drops
109 Triamterene
110 Trimethoprim
111 Tropicamide
112 Verapamil Injection
113 Vinorelbine Injection

3. Revision/upgradation of General chapters for the next VIIth edition of IP.

The following 15 General Chapters were revised/ upgraded for the next VIIth edition of IP in view of the latest technology developments and to harmonise with other international pharmacopoeias.

2.3.51. 2-Ethylhexanoic Acid
2.3.53. Ammonium
2.3.55. Fluorides
2.4.35. Bulk Density and Tapped Density of Powders
2.4.36. Completeness of Solution
2.4.37. Crystallinity
2.4.38. Specific Surface Area
2.4.39. Mass Spectroscopy
2.5.11. Polymorphism
2.4.17.Thin-Layer Chromatography
2.4.27. Refractive Index
2.4.29. Weight Per Milliliter and Relative Density (Specific Gravity)
2.4.34. Nuclear Magnetic Resonance Spectrometry
2.5.7. Particle Size Distribution Estimation
2.5.8. Optical Microscopy: Particle Size by Microscopy

4. Amendment list 3 to IP 2010

Worked on the queries/suggestions received from different stakeholders including pharma industries and after discussing and taking views of the subject expert group for IP, the same is finalized and put up on website for appropriate time and released on 11.04.2012 by the Secretary-cum-Scientific Director of IPC. Total more than 32 amendments taken place in the following monographs/tests.

AMENDMENTS

2.2.10. Microbiological Assay of Antibiotics
2.3.21. *N*,*N*-Dimethyaniline. Page 83
2.3.27. Hydroxyl Value. Page 85
Inhalation Preparations. Page 726
Microbial contamination. Page 740
Adrenaline Injection. Page 779
Ampicillin. Page 2879
Ampicillin Sodium. Page 2880
Ampicillin Injection. Page 2880
Ampicillin Trihydrate. Page 2881
Bupivacaine Hydrochloride. Page 933
Carvedilol Tablets. Page 992
Cinnarizine. Page 1088
Dextrose. Page 1190
Docetaxel Trihydrate. Page 1242
Doxycycline Hydrochloride. Page 1257

Specific optical rotation. Line 1
Imipenem. Page 1486
Miconazole Nitrate. Page 2933
Neotame. Page 1769
Ondansetron Oral Solution. Page 1818
Paracetamol Oral Suspention. Page 2940
Phenoxyethanol. Page 2942
Simvastatin Tablets. Page 2104
Streptomycin Sulphate. Page 2161
Sulphadiazine. Page 2169
Sulphadiazine Tablets. Page 2170
Telmisartan Tablets. Page 2960
Thiopentone Sodium. Page 2216
Thiopentone Injection. Page 2217
Travoprost Eye Drops. Page 2251
Zoledronic Acid. Page 2339

5. Amendment list 4 to IP 2010

Worked on the queries/suggestions received from different stakeholders including pharma industries and after discussing and taking views of the subject expert group for IP, the same is finalized and put up on website for appropriate time and released on 12.09.2012 by the Secretary-cum-Scientific Director of IPC. Total more than 77 amendments taken place in the following monographs/tests.

AMENDMENTS

General Notices. Page 11, 713, 1731
2.2.9. Microbial Contamination in Non Sterile Products. Page 37
4.3. Indicators and Indicator Test Papers. Page 623
4.5. Volumetric Reagents and Solutions.
Amlodipine Tablets. Page 807
S-Amlodipine Besylate. Page 808
Amphotericin B. Page 820
Ampicillin Trihydrate. Page 2881
Aspirin. Page 2882
Azithromycin. Page 857
Barium Sulphate. Page 872
Compound Benzoic Acid Ointment. Page 887
Bupivacaine Injection. Page 934
Butylparaben. Page 942
Cefaclor Oral Suspension. Page 995
Cefuroxime Axetil. Page 1026
Cephalexin. Page 1031
Cholecalciferol Tablets. Page 2896
Ciclesonide Inhalation. Page 1083
Clarithromycin. Page 1101
Clomipramine Capsules. Page 1111
Clopidogrel Tablets. Page 1119
Absorbent Cotton. Page 1137
Crospovidone. Page 1141
Diclofenac Tablets. Page 2900

6. Amendment list 5 to IP 2010

Worked on the queries/suggestions received from different stakeholders including pharma industries and after discussing and taking views of the subject expert group for IP, the same is finalized and put up on website for appropriate time and released on 11.03.2013 by the Secretary-cum-Scientific Director of IPC. Total more than 92 amendments taken place in the following monographs/tests.

AMENDMENTS

2.4.22.Optical Rotation and Specific Optical Rotation. Page 143
2.4.26. Solubility
2.4.2. Atomic Absorption Spectrometry. Page 109
2.4.4. Flame Photometry. Page 110
2.5.2. Dissolution Test. Page 189
4.2. General Reagents.
4.3. Indicators and Indicator Test Papers
4.5. Volumetric Reagents and Solutions.
5.2. Biological Indicators. Page 639
Capsules. Page 721
Alprazolam. Page 786
Alprazolam Tablets. Page 787
Amphotericin B. Page 820
Ampicillin Sodium. Page 824
Ampicillin Injection. Page 825
Atenolol. Page 847
Atenolol Tablets. Page 848
Atorvastatin Tablets. Page 850
Azithromycin Oral Suspension. Page 860
Benzhexol Hydrochloride. Page 884
Calcitriol Capsules. Page 961
Cefadroxil Oral Suspension. Page 2891
Cefotaxime Sodium Injection. Page 1017
Cefpodoxime Tablets. Page 1020
Citric Acid Monohydrate. Page 1100
Colchicine and Probenecid Tablets. Page 1132
Crosscarmellose Sodium. Page 1139
Dapsone. Page 1162
Dicyclomine Tablets. Page 1206
Activated Dimethicone. Page 1230
Disodium Edetate. Page 1234
Donepezil Hydrochloride. Page 1248
Donepezil Tablets. Page 1249
Doxofylline Tablets. Page 1254
Efavirenz, Emtricitabine and Tenofovir Tablets. Page 2904
Enoxaparin Sodium. Page 1276
Enoxaparin Injection. Page 1279
Ephedrine Oral Solution. Page 1281
Erythromycin. Page 1290
Erythromycin Tablets. Page 1291
Ethinyloestradiol Tablets. Page 1307

8. Verification of Analytical methods for IP

The AR&D team is vigorously involved in analytical verification of various tests in the existing monographs of IP-2010/Addendum 2012 to IP 2010 and the monographs drafted for next edition of IP. Carried out verification of analytical method for drugs samples received from various Stakeholders in the AR&D Division for verification of different tests of IP monographs. During this period following tests in mentioned samples were verified.

1. Verification of related substance of Ampicillin Trihydrate as per IP & BP.
2. Verification of water content in Secnidazole API.
3. Verificaion of Nevirapine Tablets, identification test by UV.
4. Verification of dissolution test in Escitalopram Tablets.
5. Verification of Solubility test in Rizatriptan Benzoate.
6. Verification of Related Substance test in Amikacin Sulphate.
7. Verification of Assay in Bupivaccine HCl Injection.
8. Verification of Assay of Olanzapine Tablets.
9. Verification of Solubility in Atorvastatin Calcium.
10. Verification of FTIR Spectra of Citric Acid monohydrate & anhydrous citric acid.
11. Verification of solubility of Escitalopram Oxalate.
12. Verification of Disintegration time for Ondansetron Orally Disintegration Tablets.
13. Verification of LOD/Water content in Cefotaxime Sodium.
14. Verification of FTIR spectra of Fumaric Acid.
15. Verification of water content in Imitanib Mesylate.
16. Verification of Assay in Zinc Sulphate Dispersible Tablets.
17. Verification of Uniformity of content in Atorvastatin Tablets.
18. Verification of Solubility in Dapsone.
19. Verification of Related Substance test in Ondansetron Tablet.
20. Verification of Solubility in Cefixime.
21. Verification of Dissolution of Levonorgestrel Tablets.
22. Verification of Appearance of solution, light absorption & description in Irinotecan hydrochloride.
23. Verification of Assay of Sodiumcarboxymethylcellulose Eye Drops.
24. Verification of Assay & related substance in Citicolin.
25. Verification of monograph of Lamivudine & Zidovudine Tablets.
26. Repeated verification of water content of Imitanib Mesylate.
27. Verification of Assay of Psoralen.
28. Verification of Dissolution of Terbutaline Sulphate Tablets.

09. Development of Veterinary Monographs (IVth Vol. of IP-2014)

Organized and coordinated the work related to the development of veterinary monographs for the 4th volume of next edition with the expert group of veterinary manufacturers under the chairmanship of Dr. Rishendra Verma, IVRI, Izatnagar. The first workshop was arranged on 23rd - 24th Jan-2013 at IPC-IPL, GZB.

10. Development of New Drugs Monographs

Reviewed and rechecked more than 30 monographs of New Drugs received and analyzed in Reference Standard Division and developed by them for the next edition of IP.

11. IP Reference Standards Developments:

Organized and co-ordinated for development of IPRS at Reference Standard Division by developing IPRS vial and their packing, cold room facility and for making availability of candidate material from the stakeholders. Co-ordinated the analysis of these candidate material in Reference Standard Division. The list of available IPRS is reached upto 150.

12. WHO Work for International Pharmacopoeia

Participated regularly for the development of the monographs for the WHO/International Pharmacopoeia from time to time. Following drugs monographs were checked and commented upon during this period which was received from WHO, Geneva.

1. Monograph of Fluconazole
2. Monograph of Fluconazole Injection
3. Monograph of Sulphamethoxazole and Trimethoprim Intravenous Infusion
4. Monograph of Sulphamethoxazole and Trimethoprim Oral Suspension

13. NABL (ISO-IEC/17025:2005)Accreditation of IPC-IPL

Worked for accreditation from National Accreditation Board for Testing and Calibration Laboratories of DST, New Delhi. Dr. Raman Mohan Singh was designated as **Quality Manager** for the purpose of Accreditation of IPC-IPL from NABL. Supervised and co-ordinated the work for preparation for the same with AR&D and Reference Standard Division and other Divisions. IPC-IPL assessed successfully for the NABL (ISO/IEC/17025:2005) accreditation for its testing facility in the field of Chemical as well in Biological Testing.

Seminar & Meetings

Seminars/ Training Programmes / Symposia / Workshops / Meetings attended:

Following meetings / programmes were held during April,2012- March,2013.

1. Attended USP-International Training Programme at USP, Head Quarter, Rockville, M.D.,USA by the delegation of Dr. Raman Mohan Singh, Dr. P.K.Saini and Mr. Anuj Prakash on 29.4.12 to 5.5.12, organized by IPC-USP under MOU of collaboration.

2. 24th Scientific Body meeting was held at IPC, Ghaziabad on 12.05.2012.

3. Delegation from Tanzania Government visited IPC, Ghaziabad on 21.06.2012.

4. USP, CEO Dr. Rogger Williams & other officials of USP visited IPC. They interacted and a brief meeting was held at IPC on 18.07.2012 with the employees of IPC.

5. A meeting/discussion at NIB, Noida on 18.07.2012 on Biological Standards with Scientific Delegation from USP, Rockville was attended by IPC officials.

6. A meeting of expert committee on Radio Pharmaceutical monographs for IP was held on 13.08.2012 at IPC, Ghaziabad.

7. 25th Scientific Body meeting was held at IPC, Ghaziabad on 29.08.2012.

8. Attended seminar on "International Seminar on Patient Safety & Drug Detection Technology" held at New Delhi on dated 10.09.2012 to 11.09.2012 and organized by MOH&FW at India Habitat Centre, N. Delhi.

9. IPC staff attended the IDMA- APA Pharmaceutical Analyst Convention at Hyatt regency, Mumbai on dated 21.09.2012 to 22.09.2012.

10. IPC officials attended a Pharmacopoeial Education Programme on "validation and verification of compendial procedures" at Hyderabad on 05.10.2012 to 06.10.2012 organised by USP, India.

11. Attended 2nd Sceintific Body Meeting of Pharmacopoeial Commission for Indian Medicines (PCIM) on dated 12.10.2012 at CCRAS, N.Delhi.

12. A meeting was conducted at RS Iyer Hall, IPC on 27.10.2012 with Padam Shree Dr. Nitya Anand, Ex-chairman of Scientific Body for various scientific and technical issues.

13. Attended 8th meeting for drafting of monographs and General Chapters on Radiopharmaceuticals for IP on dated 10.11.2012 at Tata Memorial Hospital, Mumbai.

14. Attended 64th meeting of Indian Pharmaceutical Congress on 7.12.2012 to 9.12.2012 at SRM University, Chennai.

15. A meeting was held on 01.01.2013 at IPC under the Chairmanship of Prof. B. Suresh, Chairman Scientific Body on the occasion of Foundation Day of IPC.

16. Attended Expert Committee meeting on dated 18.01.2013 at Hyderabad.

17. Attended a meeting on Veterinary monographs for IP on dated 23.01.2013 to 24.01.2013 at IPC, Ghaziabad.

18. Attended a seminar on "Accessibility to Quality Medicine in the supply chain" at New Delhi on dated 15.02.2013.

19. Attended Manipal-IPC Annual Commemoration Symposium and Annual Day on dated 14.02.2013 to 15.02.2013 at Manipal University, Manipal.

20. Attended IPC-USP Joint Pharmacopoeial Education Programme on dated 19.02.2013 at Gateway Hotels Ummed Taj, Gujarat.

21. 26th Scientific Body meeting held at Malviya Bhawan, New Delhi on dated 23.02.2013.

22. A meeting was held at IPC, Ghaziabad with the expert group for developing IP monographs on Radiopharmaceutical preparations on dated 20.03.2013.

LIBRARY AND INFORMATION CENTRE

About the Library & Information Centre:

The IPC Library & Information Centre is one of the leading Pharmacopoeial Library & Information Centre of the country. The library & Information Centre aims to be a leading Library & Information Centre in all the fields of Pharmacopoeial research areas and support IPC in its basic function to update regularly the standards of drugs commonly required for treatment of diseases prevailing in this Country. The IPC Library & Information Centre continues to expand its resource and activities to provide valuable Library & Information Services to support Scientific and Pharmacopoeial work. The Library & Information Centre makes its resources available and useful to the Scientists, Health Professionals and Researchers preserve latest collection of knowledge and creativity for future generations. The Library & Information Centre aims to collect, store, and disseminate information to acquire new products and services. The Library & Information Centre houses an excellent collection of more than 11,000 documents including books, periodicals, Indian & International Standards, CD-ROMs, other Non-Print Materials, and Pharmacopoeias etc. of different Countries. The Library & Information Centre also subscribes 37 national and international scientific journals on different subjects to keep up-to-date knowledge in the field of Pharmacopoeial, Pharmaceuticals and Drugs Standardization etc. It also aims to build a comprehensive collection of back volumes of journals in all these fields and in-house 2720 collection of bound volume journals. The Library & Information Centre apart from users from the IPC is open to other users of other GOI Departments, Universities and Institutes for reference.

Mission:

The mission of Library & Information Centre is to acquire organizes, provide access to, maintain, secure, and preserve all the collections safely. The collection of the Library & Information Centre is constantly being enlarged and enriched every year by acquisition of latest books, reports, serials, bound volumes of journals periodicals and non-book materials etc.

Library & Information Centre (Section):

The Library & Information Centre has open access system for self arrangement for users. Books are processed by using AACR-II code for cataloguing and Dewey Decimal Classification. The Call Number in the OPAC helps in locating the books on the shelves. Books are arranged on the shelves in numerical order from 000-999. The IPC Library & Information Centre divided in to 5 Sections:

- Circulation Section
- Periodical Section
- Reference Section
- Reprographic Section
- Internet Section

PROCUREMENT OF BOOKS:

The Library & Information Centre houses an excellent collection of more than 11,000 documents including books, Indian & International Standards, and Pharmacopoeias of different Countries. The IPC Library & Information Centre has procured the books to support Scientific, Pharmacopoeial and Administrative work during the year **(**01/04/2012 – 31/03/2013) as appended below: -

S. No.	ITEMS NAME	QUANTITY
1.	Total Books Procured	**439**

PROCUREMENT OF NON-BOOK MATERIALS:

The IPC Library & Information Centre caters to the needs of scientists of the Commission, Health professionals, and researchers from within and outside the Country. The IPC Library & Information Centre has also procured the following non-book materials during the year **(**01/04/2012 – 31/03/2013): -

S.No.	ITEMS NAME	QUANTITY
1.	CD/DVD-ROM	**6**
2.	USB Flash Drive	**3**
3.	Theses/Dissertations/Training Report	**8**
4.	Magazines	**17**
5.	Newspaper	**8**

SUBSCRIPTION OF JOURNALS:

The Library & Information Centre has subscribed 37 national and international scientific journals on different subjects to keep up-to-date knowledge in the field of Pharmacopoeial, Pharmaceuticals and Drugs Standardization etc.

DIGITALIZATION OF LIBRARY & INFORMATION CENTRE:

As part of the ongoing modernisation exercise, the Library & Information Centre has changed its face by installing FineDocs Document Management Software. The Document Management Software is for 5-Users and preserved Indian Pharmacopoeia with addendum since 1957, National Formulary of India (NFI) and Bound Volume of Journals (All issues of 19 Titles since 1965). The Users can easily access the relevant information through this software and also save the data in mass storage, take print out, copy or edit etc. The software also allows the free text searching.

LIBRARY & INFORMATION CENTRE SERVICES DURING THE YEAR 01/04/2012 – 31/03/2013:

The IPC Library & Information Centre provides the following services during the year 01/04/2012 to 31/03/2013 to support Scientific, Pharmacopoeial and Administrative work: -

i) Document Delivery Services:

The IPC Library & Information Centre has issued/consulted approximately 326 books to its staff during the year 01/04/2012 to 31/03/2013.

ii) Reference Service:

The Library & Information Centre maintains a separate reference collection consisting of rare and costly reference books on various areas of science. The IPC Library & Information Centre provided the reference service to staff members and external users. Approximately 4854 books has been consulted during the year 01/04/2012 to 31/03/2013.

iii) CAS and SDI Service:

The Library & Information Centre provided the facility of Selective Dissemination of Information (SDI) and Current Awareness Services (CAS) to the staff members and outside visitors of library during the year.

iv) Indexing and Abstracting:

The Library & Information Centre provided the Index and Abstracts of subscribed national and internationals journals on monthly basis to the staff members and outside visitors of library during the year.

v) News Paper Clipping:

The Library & Information Centre provided the news paper clipping and other news items from Government, Pharmaceutical Industry and other areas on weekly basis to the staff members and outside visitors of library during the year.

.

vi) Reprographic Services:

The Library & Information Centre provided the photocopy service to their users. This section has officially photocopied approximately 1341 pages during the year 01/04/2012 to 31/03/2013.

vii) Electronic Information Resource Access:

The Internet Section of Library & Information Centre is equipped with 10 computers with printer and latest configuration. The staff members including PvPI Technical Associates have utilized the service during the year.

viii) CD/DVD-ROM Database search:

The Library & Information Centre provides the CD/DVD-ROM database search facility to their staff members. The CD-ROM of British Pharmacopoeia, European Pharmacopoeia, United State Pharmacopoeia, USB Flash Drive of USP 2013, International Pharmacopoeia, DVD of Indian Pharmacopoeia, and Pharmacokinetik Profiling in Drug Research have been searched during the year 01/04/2012 to 31/03/2013.

LIBRARY & INFORMATION CENTRE EXPENDITURE:

The total expenditure of the IPC Library & Information Centre is `1,13,23,929/- during the year 01/04/2012 to 31/03/2013.

TRAINING PROGRAMME:

The Library & Information Centre provided the training programme to students, research scholars and officials from Institutes, Universities and Government Departments during the year 01/04/2012 to 31/03/2013 taking into account their professional background and needs for meeting the challenges of current times. During the year 8 students/research scholars have undergone training from different departments of Indian Pharmacopoeia Commission.

Moreover, during the year many students, research scholars and Officials from GOI have visited the Indian Pharmacopoeia Commission like from Karnataka State Drugs Control, CSIR-NISCAIR, DIPSAR, KIET School of Pharmacy, Gitarattan International Business School.

PUBLICATION DIVISION

INTRODUCTION

Indian pharmacopoeia Commission (IPC) is an autonomous institution of the Ministry of Health & Family Welfare, Government of India. Basic function of Indian Pharmacopoeia Commission is to update regularly the Standards of Drugs commonly required for treatment of diseases prevailing in this region. IPC regularly publishes official documents for improving Quality of Medicines by way of adding new and updating existing monographs in the form of **Indian Pharmacopoeia (IP)** whereas **National Formulary of India (NFI)** promotes rational use of generic medicines. IPC also publishes **Guidance Manual for Compliance of Indian Pharmacopoeia (IP)** in collaboration with Central Drugs Standard Control Organization & WHO-Country Office intended to enable the users of IP to perform the activities related to performance of the tests or associated activities prescribed in the IP and also to understand or interpret the requirements of IP for proper compliance of the requirements thereof. The latest Edition of **Indian Pharmacopoeia 2014** is under printing and it will be published at the earliest.

Indian pharmacopoeia Commission (IPC) also publishes **Pharmacovigilance Programme of India (PvPI)** Newsletter on Quarterly basis. Phamacovigilance is an integral part of healthcare delivery systems. It promotes health professionals regarding drug safety profile by reviewing case reports of various ADR monitoring centres submitted to National Coordination Centre- Pharmacovigilance Prgoramme of India (PvPI).

PUBLICATIONS OF IPC

The following Official Publications are published by the Indian Pharmacopoeia Commission during the financial year 01.04.2012 to 31.03.2013. The details are as appended below:-

S. No.	TITLE OF THE PUBLICATION
1.	PvPI Newsletter Vol. 2, Issue 2, 2012
2.	Guidance Manual for Compliance of Indian Pharmacopeia (IP)
3.	PvPI Newsletter Vol. 2, Issue 3, 2012

SALE & DISTRIBUTION OF IPC PUBLICATIONS

The sales and distribution of IPC Publications during the financial year 01.04.2012 to 31.03.2013 are as appended below: -

Status of Sales & Distribution of IPC Publications w.e.f. 01 April 2012- 31 March 2013.

S.No.	Publication	Total No. of Copies/Sets Printed	Current Status (As on 01/04/2012 to 31/03/2013		Revenue Generated
1.	I.P. -2007	4894	Sold	2	Total revenue generated =` **22,500/-**
			Comp.	24	
2.	I.P. -2010	3000	Sold	311	Total revenue generated = ` **50,56,000/-**
			Comp.	19	
3.	DVD of I.P.- 2010	3000	Sold	23	Total revenue generated = ` **4,60,000/-**
			Comp.	26	
4.	I.P. -2010 Addendum 2012	1500	Sold	469	Total revenue generated = ` **11,44,200/-**
			Comp.	32	
5.	NFI-2011	30000	Sold	12376	Total revenue generated = ` **57,95,570/-**
			Comp.	461	
6.	Guidance Manual for Compliance of IP	1000	Sold	125	Total revenue generated = ` **34,250/-**
			Comp.	127	

Total = ` 1,25,12,520/-

(Total Revenue Generated = Rupees One Crore Twenty Five Lacs Twelve Thousand Five Hundred Twenty only)

Pharmacovigilance Programme of India

Ministry of Health & Family Welfare, Government of India launched a nationwide Pharmacovigilance Programme of India (PvPI) to monitor the safety of medicine. Indian Pharmacopoeia Commission (IPC) an autonomous institution, under the ministry of Health & Family Welfare, Government of India, Ghaziabad is functioning as National Coordination Centre (NCC) for PvPI since April 15th 2011. ADRs are collected by various ADR Monitoring Centres across the country and reported to NCC. PvPI is functioning with the mission to ensure that the benefits of medicine outweigh the risks and thus safeguard the health of the population. The objective is to

- monitor ADRs in Indian population
- create awareness amongst health care professionals about the importance of ADR reporting in India
- monitor benefit-risk profile of medicines
- generate independent, evidence based recommendations on the safety of medicines
- support the CDSCO for formulating safety related regulatory decisions for medicines

The health care professionals collecting data of adverse events related to drugs marketed in India, can report to their respective ADRs Monitoring Centres (AMCs) which in turn is submitted to NCC through VigiFlow. The submitted data is collated and evaluated for quality by the various panels and groups of NCC-PvPI, IPC Ghaziabad. NCC is responsible for committing the reports to Uppsala Monitoring Centre (UMC) in Sweden and to communicate the scientific outcome to CDSCO for their regulatory intervention.

As on date, there are 90 AMCs spread across the four zonal offices of CDSCO are functioning under NCC. ADRs related to drugs, biologicals including blood and blood related products, recombinant DNA derived therapeutic products, vaccines and medical

devices are being reported to these AMC's, in a specially designed ADR reporting form, which are transmitted to NCC after proper evaluation at each level.

In order to provide training and technical support to the newly inducted AMCs, four Training and Technical Support Centres at regional level were identified by NCC. These include Post Graduate Institute of Medical Education and Research, Chandigarh (North), JSS Medical College, Mysore (South), Institute of Post Graduate Medical Education and Research, Kolkata (East), Seth GS Medical College and KEM Hospital, Mumbai (West).

To disseminate information on suspected adverse reactions to health products occuring in humans and regulatory decisions to the stakeholders NCC publishes "PvPI Newsletter".

Mission

Safeguard the health of the Indian population by ensuring that the benefits of use of medicine outweighs the risks associated with its use.

Vision

To improve patient safety and welfare in Indian population by monitoring the drug safety and thereby reducing the risk associated with use of medicines.

Objectives

To create a nation-wide system for patient safety reporting.

To identify and analyse the new signal (ADR) from the reported cases.

To analyse the benefit - risk ratio of marketed medications.

To generate the evidence based information on safety of medicines.

To support regulatory agencies in the decision-making process on use of medications.

To communicate the safety information on use of medicines to various stakeholders to minimise the risk.

To emerge as a national centre of excellence for Pharmacovigilance activities.

To collaborate with other national centres for the exchange of information and data management.

To provide training and consultancy support to other National Pharmacovigilance Centres located across globe.

Scope

Since there exist considerable social and economic consequences of adverse drug reactions and the positive benefit/cost ratio of implementing appropriate risk management â€“ there is a need to engage healthcare professionals and the public at large, in a well structured programme to build synergies for monitoring adverse drug reactions in the country.

The purpose of the Pharmacovigilance Program of India is to collate data, analyze it and use the inferences to recommend informed regulatory interventions, besides communicating risks to healthcare professionals and the public.

Implementation of PvPI

Indian Pharmacopoeia Commission understands the need for establishing local hospital based centres across the nation for the better patient safety. It is important to monitor both the known and hitherto unknown side effects of medicines in order to determine any new information available in relation to their safety profile. In a vast country like India with a population of over 1.2 billion with vast ethnic variability, different disease prevalence patterns, practice of different systems of medicines, different socioeconomic status, it is important to have a standardized and robust Pharmacovigilance and drug safety monitoring programme for the nation.

Short term goals

1. To develop and implement Pharmacovigilance system in India.
2. To enroll, initially, all MCI approved medical colleges in the program covering north, south, east and west of India.

3. To encourage healthcare professionals in reporting of adverse reaction to drugs. vaccines, medical devices and biological products.
4. Collection of case reports and data.

Long term goals

1. To expand the Pharmacovigilance programme to all hospitals (govt. & private) and centres of public health programs located across India.
2. To develop and implement electronic reporting system (e-reporting).
3. To develop reporting culture amongst healthcare professionals.
4. To make ADR reporting mandatory for healthcare professionals.

PvPI - Programme Communication



Seminars/ Training Programmes / Symposia / Workshops / Meetings attended:

- NCC-PvPI officials participated in the 'National symposium on Translational Pharmacovigilance' organized by department of Pharmacology, PGIMER, Chandigarh on 14th April 2012.
- NCC-PvPI submitted 30 ICSRs on *Pioglitazone* and150 ICSRs on *Statins* to CDSCO for regulatory intervention in India.
- NCC-PvPI delivered a lecture on 'Introduction to Pharmacovigilance and Pharmacovigilance programme of India' during the workshop on to create awareness among health care professionals organized by Department of Pharmacology, SMS Medical College, Jaipur on September 17, 2012.
- NCC-PvPI delivered a lecture on 'Appraisal about the PvPI and the modalities of reporting the ADRs' to the Clinical faculty, PGs and other health care professionals at Department of Pharmacology, UCMS & GTB Hospital, New Delhi on September 19, 2012.
- The Second Working Group-PvPI Meeting was held on September 28, 2012 under the Chairmanship of Secretary-cum-Scientific Director, Indian Pharmacopoeia Commission, Ghaziabad to discuss and resolve various issues of PvPI.
- The 1st Steering Committee was held on 28th December 2012 at DCG(I) office, FDA Bhawan, New Delhi to give a direction for effective functioning of PvPI.
- NCC-PvPI published Issue-4, Volume-2 PvPI news letter in December 2012 with special emphasis on the ADRs reporting culture in India & Insulin-induced weight gain in diabetic patients.
- The Third Working Group of PvPI meeting was held on 29/01/2013 to discuss the various issues at DCG(I) office, FDA Bhawan, New Delhi.

- NCC-PvPI provided technical support to organize a workshop on 'National symposium on Pharmacovigilance and ADRs monitoring' to create awareness among healthcare professionals on 9th and 10th February 2013.
- AEFI division from MOH & FW, Govt of India visited at NCC-PvPI on 28th February 2013 to discuss the various issues on ADRs related to vaccines and for better coordination.
- PGIMER, Chandigarh in collaboration with NCC organized a VigiFlow training for the personnel's involved in AMCs north zone under PvPI on 22nd February 2013.

IPC Staff (as on 31st March, 2013)

Name	Designation
Dr. Gyanendra Nath Singh	Secretary-cum-Scientific Director

Technical Staff

Research & Development Division

Dr. Raman Mohan Singh	Principal Scientific Officer
Dr. S. C. Mathur	Scientific Officer
Mr. Dinesh Kumar Sharma	Scientific Assistant
Mr. Pawan Kumar Saini	Scientific Assistant

Pharmacology and Microbiological Division

Dr. Jai Prakash	Principal Scientific Officer
Dr. Nishant Dafale	Senior Scientific Officer
Dr. V. Kalaiselvan	Senior Scientific Officer
Mr. Alok Sharma	Scientific Officer
Mr. Manoj Kumar Pandey	Scientific Assistant
Ms. Akanksha Bisht	Scientific Assistant
Mrs. M. Kalaivani	Scientific Assistant
Mr. Prasad Thota	Scientific Assistant

Pharmaceutical Chemistry & Reference Substances Division

Dr. Anil Kr Teotia	Senior Scientific Officer
Dr. Robin Kumar	Senior Scientific Officer
Mr. Anuj Prakash	Senior Scientific Officer
Mrs. Meenakashi Dahiya	Senior Scientific Officer
Mr. Y. K. Kush	Scientific Assistant
Mr. Satya Prakash Tyagi	Scientific Assistant
Smt. Ritu Tiwari	Scientific Assistant
Mr. Utpal Nandi	Scientific Assistant
Mr. Ravindra Verma	Scientific Assistant
Mr. Ramji Rathore	Scientific Assistant
Mr. Gaurav Kumar	Scientific Assistant
Ms. Manisha Trivedi	Scientific Assistant
Mr. C. Saravanan	Scientific Assistant

Non-Technical Staff

Library and Publication Division

Mr. K. K. Singh	Library & Information Officer
Mr. B. D. Sharma	Senior Laboratory Attendant

Store Division

Mr. Manish Jain	Store Officer
Mr. Bijender Kumar	Laboratory Attendant

Administration and Cash Division

Mr. I. J. S. Oberoi	Admn. Officer (I/C)
Mr. Udai Pal	Hindi Translator
Mr. Chandan Kumar	Finance & Accounts Officer
Ms. Renu Kapoor	Upper Divisional Clerk
Mr. Satyaveer Singh	Senior Laboratory Attendant
Mr. Rajendra Kumar Sharma	Peon

Statements of Account
2012-13

Auditors Report

1. We have audited the attached balance Sheet of the *Indian Pharmacopoeia Commission* as at 31st March, 2013 and the Income and Expenditure Account along with Receipts & Payment Account for the year ended on that date annexed thereto. These Financial Statements are the responsibility of the Commission's Management. Our responsibility is to express an opinion on these Financial Statement based on our audit.

2. We have conducted our Audit in accordance with Auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the Financial Statements are free of materials misstatement. An Audit included examining on test basis evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing accounting principles used and significant estimates made by management, as well as evaluating the overall Financial Statement presentation. We believe that our audit provide a reasonable basis for expressing our opinion.

3. Attention is invited to:

   Note No. (3),(4),(5) & (12).

   Re: Non provision of Leave Encashment & Gratuity. The impact of the same on tax liability, if any could not be assessed and quantified because of amount of bonus has not yet been finalized.

4. We report that

   a) In our opinion, the Balance Sheet and Income & Expenditure dealt with by this report broadly comply with the Accounting Standards issued by the Institute of Chartered Accountants of India.

   b) We have obtained all the information and explanations, which to the best of our knowledge and belief were necessary for the purpose of our audit.

5. In our opinion proper books of accounts have been maintained by the Commission so far as it appears from our examination of books.

6. The Balance Sheet and the Income & Expenditure Account dealt with by this report are in agreement with the books of accounts.

Subject to our observation / comments in Para 3 above, in our opinion and to the best of our information and according to the explanations given to us, the accounts and the Schedules annexed together with the significant accounting policies and notes thereon exhibit a true and fair view:

a) Balance Sheet of the state of affairs of the Commission as at 31st March, 2013 and

b) Income & Expenditure Account for the year ended 31st March, 2013.

FOR PARY & CO.
CHARTERED ACCOUNTANTS
(FR No. 007288C)

Yogesh Malik
F.C.A., D.I.S.A. (ICA)
Sr. Partner
M.No. 074635

PLACE: GHAZIABAD
DATE: 02.09.2013

INDIAN PHARMACOPOEIA COMMISSION
Ministry of Health & Family Welfare
Sector - 23, Raj Nagar Ghaziabad - 201002

BALANCE SHEET AS AT 31st MARCH 2013

(Amount in Rs.)

CORPUS/CAPITAL FUND AND LIABILITIES	Schedule	Current Year	Previous Year
Corpus / Capital Fund	1	86,35,10,074.00	85,36,92,868.00
Current Liabilities and Provisions	2	60,82,100.00	47,58,532.00
TOTAL		**86,95,92,174.00**	**85,84,51,400.00**

ASSETS	Schedule	Current Year	Previous Year
Fixed Assets	3		
Gross Block		87,63,89,794.00	83,37,50,720.00
Less : Depreciation		8,78,20,737.00	5,91,31,244.00
Net Block		78,85,69,057.00	77,46,19,475.00
Investment in Fixed Deposits		2,44,18,504.00	5,49,21,915.00
Intrest Accrued on Investment		1,99,926.00	14,05,696.00
Current Assets, Loans & Advances	4	5,64,04,687.00	2,75,04,314.00
TOTAL		**86,95,92,174.00**	**85,84,51,400.00**
SIGNIFICANT ACCOUNTING POLICIES AND NOTES ON ACCOUNTS	12		

As per our report of even date attached.

For P A R Y & CO.
Chartered Accountants
(FR No. 007288C)

FOR INDIAN PHARMACOPOEIA COMMISSION

Dr. G. N. Singh
(Secretary cum scientific Director)

Yogesh Malik
F.C.A, D.I.S.A (ICA)
Sr. Partner
M. No. 074635

Chandan Kumar
(Finance & Accounts Officer)

I.J.S Oberoi
(Administrative Officer)(i/c)

Place:Ghaziabad
Date: 02.09.2013

INDIAN PHARMACOPOEIA COMMISSION
Ministry of Health & Family Welfare
Sector - 23, Raj Nagar Ghaziabad - 201002

INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED 31st MARCH 2013

(Amount in Rs)

PARTICULARS	Schedule	Current Year	Previous Year
INCOME			
Receipts from Sales	5	1,32,85,270.00	1,31,05,240.00
Grants/Subsidies	6	7,00,81,360.00	6,28,90,577.00
Interest Earned	7	32,57,211.00	83,45,145.00
Other Income	8	1,93,992.00	20,913.00
Depreciation (as per contra)		2,48,91,966.00	2,08,89,467.00
TOTAL (A)		**11,17,09,799.00**	**10,52,51,342.00**
EXPENDITURE			
Establishment Expenses	9	4,30,12,082.00	3,72,11,395.00
Adminstration Expenses	10	2,14,26,579.00	2,16,34,672.00
Lab Services - Operation & Maintainance Exp	11	54,59,991.00	23,04,628.00
Depreciation (as per contra)		2,48,91,966.00	2,08,89,467.00
TOTAL (B)		**9,47,90,618.00**	**8,20,40,162.00**
Balance being Surplus/(Deficit)		1,69,19,181.00	2,32,11,180.00
Add/(Less): Prior Period Expenses		(1,82,708.00)	(17,39,882.00)
Current year Income paid to MOH & FW		1,67,36,473.00	2,14,71,298.00
Surplus/(Deficit) carried to Corpus/Capital Fund (Total A - B)		-	-
SIGNIFICANT ACCOUNTING POLICIES AND NOTES ON ACCOUNTS	12		

As per our report of even date attached.

For P A R Y & CO.
Chartered Accountants
(FR No. 007288C)

FOR INDIAN PHARMACOPOEIA COMMISSION

Dr. G. N. Singh
(Secretary cum Scientific Director)

Yogesh Malik
F.C.A, D.I.S.A (ICA)
Sr. Partner
M. No. 074635

Chandan Kumar
(Finance & Accounts Officer)

I.J.S Oberoi
(Administrative Officer)(i/c)

Place:Ghaziabad
Date: 02.09.2013

INDIAN PHARMACOPOEIA COMMISSION
Ministry of Health & Family Welfare
SECTOR-23,RAJ NAGAR GHAZIABAD-201002

RECEIPTS AND PAYMENTS ACCOUNT FOR THE YEAR ENDED 31ST MARCH 2013

(Amount in Rs)

Receipts	Current Year	Previous Year	Payments	Current Year	Previous Year
1. Opening Balance			**1. Expenses**		
-Cash in Hand	62,847.00	51,655.00	- Establishment Expenses	4,30,12,082.00	3,59,87,218.00
-Bank Balance	82,10,159.00	8,53,85,928.00	- Administrative Expenses	2,06,07,968.00	2,04,36,567.00
-Stamps in Hand	50,433.00	-	- Lab Services- O&M Exp	54,59,991.00	31,33,632.00
			-Prior Period Expenses	1,82,708.00	17,39,882.00
2. Grants Received					
-From Government of India	11,21,60,000.00	10,36,20,000.00	**2. Payments made against funds**		
			-Advance to HLL Lifecare Limited	1,03,67,307.00	98,85,777.00
3. Interest Received:			-Advance to A & A Perodicals	39,96,619.00	31,40,786.00
-Intrest Accrued on Investment	29,11,964.00	63,27,611.00	-Advance Payment to W.H.O	-	14,200.00
-On Savings Account	3,42,847.00	20,14,434.00	-Advance to GPF-IPC	10,00,000.00	20,00,000.00
-Interest Recovered from Scooter advance	2,400.00	3,100.00	-Advances to CPWD Ghaziabad	81,07,366.00	-
			-Advances to Others	73,504.00	-
4. Other Income					
-Sale of I.P Books	62,22,700.00	1,31,05,240.00	**3. Expenditure on Fixed Assets**		
-Sale of IPRS	7,58,150.00	-	**& Capital Work-in-Progress**		
-Sale of NFI	57,95,570.00	-	-Books	81,97,366.00	13,37,921.00
-Others	4,94,250.00	-	-Building	36,90,954.00	89,88,497.00
-Other Income	1,93,992.00	20,913.00	-Computer & Pheripheral	20,96,983.00	11,01,652.00
-Sale of Tender Forms	14,600.00	-	-Cycle	-	2,900.00
			-Furniture & fixture	69,74,860.00	20,86,996.00
5. Other Receipts			-Office Equipments	15,30,359.00	64,27,750.00
-Advances to Contractors & Suppliers including prior period adjustments adjusted during the year	61,96,566.00	9,52,70,786.00	-Plant Machinery & Equipment	70,35,672.00	11,01,81,061.00
			-Vehicle	-	4,93,365.00
-Scooter Advance	31,500.00	34,000.00	**4. Refund of surplus money/loans**		
-Tour Advance	4,19,025.00	-	- To the MOH & FW	-	3,90,00,000.00
-Festival Advance	40,875.00	30,300.00	-To the MOH & FW	4,30,00,000.00	4,50,00,000.00
-License Fee Recovered	5,100.00	-	-Increase in Investments during the year	-	63,27,611.00
-Decrease in Investments during the year	3,17,09,181.00	-			
-Increase in Security Deposit/ Retention Money	1,32,000.00	-	**5.Other payments**		
-Increase in amount payable to creditors	22,10,455.00	-	-TCS Paid	4,500.00	-
			-Security deposit with Electricity Deptt.	-	1,21,738.00
			-Festival Advance	30,000.00	33,750.00
			-Tour Advance	4,18,733.00	38,225.00
			-Scooter Advance	-	61,000.00
			-Amount Recoverable From Debtors	57,68,040.00	-
			6.Closing Balances		
			-Cash in Hand	39,284.00	62,847.00
			-Bank Balance	63,58,994.00	82,10,159.00
			-Stamps in Hand	11,324.00	50,433.00
	17,79,64,614.00	**30,58,63,967.00**		**17,79,64,614.00**	**30,58,63,967.00**

As per our report of even date attached.
For P A R Y & CO.
Chartered Accountants
(FR No. 007288C)

FOR INDIAN PHARMACOPOEIA COMMISSION

Yogesh Malik
F.C.A, D.I.S.A (ICA)
Sr. Partner
M. No. 074635

Dr. G. N. Singh
(Secretary cum scientific Director)

Place:Ghaziabad
Date: 02.09.2013

Chandan Kumar
(Finance & Accounts Officer)

I.J.S Oberoi
(Administrative Officer)(i/c)

(A) SIGNIFICANT ACCOUNTING POLICIES

1. Basis of Accounting

The financial statements have been prepared as prescribed by ICAI in accordance with generally accepted accounting principles. The Indian Pharmacopoeia Commission (here and after referred as IPC) adopts accrual system of accounting but interest on advances to Employees are recognized on Cash basis.

2. Fixed Assets and Depreciation

a) Fixed assets are stated at cost less accumulated depreciation.

b) Depreciation has been provided to the extent of 95% on straight line method on the basis of rates as prescribed in schedule XIV of the Companies Act 1956. Depreciation on Library Books has been charged @ 40% on straight line method. The depreciation rates applied on various assets is given below –

FIXED ASSETS		RATES OF DEPRECIATION CHARGED
Machinery & Equipment	-	4.75%
Office Equipment	-	7.07%
Building	-	1.63%
Furniture & Fixtures	-	6.33%
Lab Equipments	-	7.07%
Vehicles	-	9.50%
Cycle	-	7.07%
D.G Sets	-	4.75%

c) In respect of additions to fixed assets made during the year, depreciation has been provided for the full year and in respect of sale/disposal of fixed assets, no depreciation has been provided but it has no financial implication due to this deviation from the prescribed provisions of the ICAI.

d) The depreciation has been charged to the grant Corpus Fund and is recognized in the Income & Expenditure account over the useful life of the asset as a contra item as per AS-12 Prescribed by ICAI.

3. Grant In Aid

a) The grants in aid received from Ministry of Health & family Welfare, Government of India is accounted for on accrual basis. Accordingly, any deficit/surplus of grant has been shown as Grant receivable/payable to the MOH & FW.

b) Grant is charged to the revenue to the extent of expenditure incurred as all the Incomes received by the IPC have been transferred to the MOH & FW.

c) The grants utilized for the purchase of fixed assets have been shown under the head of Corpus Fund.

d) Further grants utilized for Purchase of Fixed Assets have also been shown under the head of Corpus Fund.

4. Employee Remuneration & Benefits

All Retirement and other Terminal Benefits such as Gratuity, Leave Encashment and Bonus etc are not accounted on year to year basis and the same are recognized in the year of retirement.

5. Revenue Recognition

Income and expenditure are accounted for on accrual basis, as they are earned or incurred. Further all the income received by way of Sale of I.P Books & other misc. receipts has been transferred to the MOH & FW

6. Provision

A provision is recognized when an enterprise has a present obligation as a result of past event; it is probable that an outflow of resources will be required to settle the obligation, in respect of which a reliable estimate can be made. Provisions are not discounted to present value and are determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and are adjusted to reflect the current best estimates.

7. Contingent Liabilities and Contingent Assets

A disclosure for a contingent liability is made when there is a possible obligation that may, but probably will not, require an outflow of resources. Where there is a possible obligation or a present obligation but the like hood of outflow of resources is remote, no provision or disclosure is made.

(B) NOTES ON ACCOUNTS

1. The depreciation of Rs.2,48,91,966.00 has been charged to the Income & Expenditure account. Since the institute is fully aided by the Government of India, therefore depreciation is charged to the grant Corpus Fund and is recognized in the Income & Expenditure account over the useful life of the asset as a contra item.

2. During the current year corpus fund was credited by Rs. 37, 97,527.00 on account of excess depreciation charged and Rs.1,31,93,745.00 excess amount written off on books in previous year. Further, during the previous years IPC has charged deprecation on Gross Block of Assets instead of charging Depreciation individually. (i.e. Asset-wise Depreciation)

3. Provision for Leave Encashment and gratuity has not been made during the year.

4. Party balances are subject to confirmation.

5. Cheques being amount of Rs. 20,06,640.00 .have been issued to the Parties but not presented before the bank till date.

6. Liabilities are recognized to the extent information available.

7. Internal Control system of IPC needs to be Strengthen.

8. The institute has not gathered any information from suppliers/service providers about their status under Micro, Small and Medium Enterprises (Development) Act, 2006. Therefore the required information, regarding the dues outstanding to Micro, Small and Medium Enterprises as on 31.03.2013 and interest payable, if any, are not considered.

9. Financial effect of pending Court Cases cannot be ascertained on the Balance Sheet Date therefore neither the provision nor the amount of the same has been disclosed in the notes to accounts. The pending court cases are on account of C.G.H.S facility to be provided to employees, so there is no financial impact of the same on the Balance Sheet date.

10. During the F.Y a sum of Rs 2,62,63,527.00 has been charged to the Corpus fund because in the Previous Years amount Payable/Recoverable to the Ministry has been added to the Corpus Fund.

11. During the year, IPC has transferred all the receipts to MOH & FW, GOI which are earned by way of Sale of I.P Books & other misc. receipts. Further, IPC has transferred a sum of Rs 4,30,00,000.00 to the MOH & FW, which includes Income of current year as well as of previous year.

12. Advance payments in excess of actual requirement not only blocked the Government money but also results into financial loss to the Government, as the IPC is not getting any interest on these advances. The details of same are as follows:

Sl. No.	Party's Name	Amount in Rs.
1.	M/s Hindustan Life Care Limited (HLL)	2,02,53,084.00
2.	M/s A & A Periodical Subscription Agency (P) Ltd.	34,18,295.00
3.	Central Public Works Department (CPWD)	81,07,366.00

13. During the year IPC has given advance amounting to Rs.10,00,000.00 to "IPC GPF".

14. The previous year figures have been regrouped/reclassified/rearranged, wherever necessary.

For P A R Y & CO.
Chartered Accountants
(FR No. 007288C)

Yogesh Malik
F.C.A, D.I.S.A (ICA)
Sr. Partner
(M. No. 074635)

Place: Ghaziabad
Date: 02.09.2013

FOR INDIAN PHARMACOPOEIA COMMISSION

Dr. G.N Singh
(Secretary-cum -Scientific Director)

Chandan Kumar
(Finance & Accounts Officer)

I.J.S. Oberoi
(Administrative Officer)(i/c)

AUDITORS REPORT

To,

The Members,

General Provident Fund,

Indian Pharmacopoeia Commission,

Ministry of Health & Family Welfare

Government of India,

Sector-23 Raj Nagar,

Ghazibad-201002

1. We have audited the attached Balance Sheet of the Indian Pharmacopoeia Commission, General Provident Fund as at 31st March 2013 and Income & Expenditure Account along with Receipts & Payment Account for the year ended on that date annexed thereto. These Financial Statements are the Responsibility of the "IPC-GPF" Management. Our Responsibility is to express an opinion on this Financial Statements Based on our Audit.

2. Further we report that:
   a) We have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit.

   b) In our opinion proper books of accounts as required by law have been kept by the Institute so far as it appears from our examination of books.

c) The Balance Sheet and the Income & Expenditure Account dealt with by this report are in agreement with the books of accounts.

3. In our opinion and to the best of our information and according to the explanations given to us, the said accounts exhibit a true and fair view.

a) In the case of Balance Sheet of the state of affairs as at 31st March 2013; and

b) In the case of the Income & Expenditure Account Excess of Income over Expenditure for the year ended 2013.

For P A R Y & CO.
Chartered Accountants
(FRN 007288C)

Yogesh Malik
F.C.A, D.I.S.A (ICA)
Sr. Partner
(M. No. 074635)

Place: Ghaziabad
Date: 02.09.2013

INDIAN PHARMACOPOEIA COMMISSION
General Provident Fund
RECEIPTS AND PAYMENTS ACCOUNT FOR THE YEAR ENDED 31ST MARCH 2013

(Amount in Rs)

Receipts	Current Year	Previous Year	Payments	Current Year	Previous Year
Opening Balance			**Payments made out of GPF Fund**		
- Bank Balance	15,96,140.00	5,93,502.00	- Towards Withdrawls	42,03,000.00	27,68,000.00
			- Towards Final Settlement	-	4,86,852.00
GPF Receipts					
- Contribution received during the year	19,47,200.00	19,50,235.00	**Payments made towards Investments**		
- Interest on GPF	8,99,810.00	8,29,658.00	- Fixed Deposit	12,24,869.00	9,84,383.00
Interest Received			**Other payments**		
- On Bank deposits	83,702.00	47,055.00	- Advance paid during the year	-	-
- Interest on Investment	12,24,869.00	9,84,383.00	- Interest on subscription	8,99,810.00	8,29,658.00
Other Receipts			**Closing Balances**		
- Advance recovered during the year from members	-	2,60,200.00	- Bank Balance	4,24,042.00	15,96,140.00
- Loan from IPC	10,00,000.00	20,00,000.00			
Total	**67,51,721.00**	**66,65,033.00**	**Total**	**67,51,721.00**	**66,65,033.00**

As per our report of even date attached.

-

For P A R Y & CO.
Chartered Accountants
(FR No. 007288C)

FOR INDIAN PHARMACOPOEIA COMMISSION
General Provident Fund

Dr. G.N. Singh
(secretary-cum -Scientific Director)

Yogesh Malik
F.C.A, D.I.S.A (ICA)
Sr. Partner
M. No. 074635

Chandan Kumar
(Finance & Accounts Officer)

I.J.S Oberoi
(Adminstrative Officer)(i/c)

Place : Ghaziabad
Date : 02.09.2013

Income & Expenditure Account for the year Ended 31.03.2013

(Amount in Rs)

Expenditure	Current Year	Previous Year	Income	Current Year	Previous Year
Interest on subscription	8,99,810.00	8,29,658.00	Interest on Investment	10,20,199.00	12,89,016.00
Excess of Income over Expenditure	2,04,091.00	5,06,413.00	Interest on Saving A/c	83,702.00	47,055.00
Total	**11,03,901.00**	**13,36,071.00**	**Total**	**11,03,901.00**	**13,36,071.00**

Significant Accounting Policies and Notes to Accounts 4

As per our report of even date attached.
For P A R Y & CO.
Chartered Accountants
(FRN. 007288C)

FOR INDIAN PHARMACOPOEIA COMMISSION
General Provident Fund

Yogesh Malik
F.C.A, D.I.S.A (ICA)
Sr. Partner
M. No. 074635

Dr. G.N. Singh
(secretary-cum -Scientific Director)

Place : Ghaziabad
Date : 02.09.2013

Chandan Kumar
(Finance & Accounts Officer)

I.J.S Oberoi
(Adminstrative Officer)(i/c)

INDIAN PHARMACOPOEIA COMMISSION GENERAL PROVIDENT FUND
(Ministry of Health and Family Welfare)
Balance Sheet as at 31.03.2013

(Amount in Rs)

Liabilities	Schedule	Current Year	Previous Year	Assets	Schedule	Current Year	Previous Year
Capital				**Investment**			
Subscription & Contributions	**1**	1,00,63,762.00	1,14,19,752.00	Fixed Deposit with Bank	**3**	1,22,09,252.00	1,09,84,383.00
Balance being Excess of Income/Expenditure	**2**	(3,30,505.00)	(5,34,596.00)	**Current Assets**			
				Accrued Interest(Investment)		99,963.00	3,04,633.00
Current Liability				Balance in super saving Account		4,17,430.00	15,89,528.00
IPC Loan		30,00,000.00	20,00,000.00	Bank Balance 310		6,612.00	6,612.00
Total		**1,27,33,257.00**	**1,28,85,156.00**	**Total**		**1,27,33,257.00**	**1,28,85,156.00**

Significant Accounting Policies and Notes to Accounts 4

As per our report of even date attached.

For P A R Y & CO.
Chartered Accountants
(FR No. 007288C)

FOR INDIAN PHARMACOPOEIA COMMISSION
General Provident Fund

Yogesh Malik
F.C.A, D.I.S.A (ICA)
Sr. Partner

Dr. G.N. Singh
(secretary-cum -Scientific Director)

Chandan Kumar
(Finance & Accounts Officer)

I.J.S Oberoi
(Adminstrative Officer)(i/c)

Place : Ghaziabad

SCHEDULES FORMING PART OF BALANCE SHEET AS AT 31st MARCH 2013
SCHEDULE - 1 : List of Members Who Contributed towards subscriotion of "IPC-GPF"

(Amount in Rs)

Sl.No	GPF A/c No.	Name & Designation	Opening Balance as on 1.04.2012 (A)	Subscription/ Contribution (B)	Recovery (C)	Advance (D)	Withdrawal (E)	Final Settlement (F)	Interest (G)	Balance as on 31.03.2013 (A)+(B)+(C)-(D)-(E)-(F)+(G)
1	IPC/01	Dr. Jai Prakash	6,73,654.00	60,000.00	-	-	-	-	62,142.00	7,95,796.00
2	IPC/02	Dr. R.M. Singh	4,33,572.00	1,35,000.00	-	-	2,55,000.00	-	31,169.00	3,44,741.00
3	IPC/03	Shri K. K. Singh	3,66,173.00	60,000.00	-	-	-	-	35,083.00	4,61,256.00
4	IPC/04	Smt. Savita Shukla	47,821.00	-	-	-	-	-	-	47,821.00
5	IPC/05	Dr. S. C. Mathur	15,68,656.00	1,20,000.00	-	-	12,00,000.00	-	1,00,128.00	5,88,784.00
6	IPC/06	Km.Sangeeta Bhatnagar	20,59,305.00	78,000.00	-	-	-	-	1,84,937.00	23,22,242.00
7	IPC/07	Sh. Alok Sharma	75,682.00	36,000.00	-	-	70,000.00	-	4,783.00	46,465.00
8	IPC/08	Sh. M. K. Panday	2,86,149.00	60,000.00	-	-	1,95,000.00	-	10,881.00	1,62,030.00
9	IPC/09	Sh. Y. K. Kush	10,267.00	24,000.00	-	-	-	-	2,047.00	36,314.00
10	IPC/10	Sh. Satya Prakash	7,52,257.00	1,08,000.00	-	-	-	-	71,347.00	9,31,604.00
11	IPC/11	Dr. D. K. Sharma	13,36,816.00	1,20,000.00	-	-	12,50,000.00	-	59,926.00	2,66,742.00
12	IPC/12	Sh. Pawan Kr. Saini	1,07,575.00	1,14,000.00	-	-	-	-	14,901.00	2,36,476.00
13	IPC/13	Sh. Satyaveer Singh	4,36,857.00	1,65,200.00	-	-	-	-	46,245.00	6,48,302.00
14	IPC/14	Sh. B. Dayal Sharma	3,70,456.00	1,12,000.00	-	-	2,50,000.00	-	18,139.00	2,50,595.00
15	IPC/15	Smt. Ritu Tiwari	4,43,239.00	1,31,000.00	-	-	1,80,000.00	-	35,624.00	4,29,863.00
16	IPC/16	Sh. Udai Pal	40,345.00	24,000.00	-	-	40,000.00	-	2,934.00	27,279.00
17	IPC/17	Sh. I. J. S. Oberoi	70,163.00	84,000.00	-	-	63,000.00	-	5,162.00	96,325.00
18	IPC/18	Km. Renu Kapoor	10,63,587.00	1,04,000.00	-	-	-	-	98,318.00	12,65,905.00

19	IPC/19	Sh. Bijendra Kumar	4,94,302.00	1,20,000.00	-	-	-	-	49,219.00	6,63,521.00
20	IPC/20	Sh. R. K. Sharma	62,619.00	52,000.00	-	-	-	-	7,402.00	1,22,021.00
21	IPC/21	Dr. Anil Kr. Teotia	7,20,257.00	2,40,000.00	-	-	7,00,000.00	-	59,423.00	3,19,680.00
		Total	**1,14,19,752.00**	**19,47,200.00**	**-**	**-**	**42,03,000.00**	**-**	**8,99,810.00**	**1,00,63,762.00**

SCHEDULES FORMING PART OF BALANCE SHEET AS AT 31st MARCH 2013

SCHEDULE - 2 : Excess of Income/Expenditure for the year

PARTICULARS	As on 31.03.2013	As on

		31.03.2012
Opening Balance As on	(5,34,596.00)	(10,41,009.00)
Add/Less: Income/Expenditure for the year	2,04,091.00	5,06,413.00
TOTAL	(3,30,505.00)	(5,34,596.00)

SCHEDULE - 3: INVESTMENTS

FDR / Receipt NO	DATE OF INVESTMENT	AMOUNT INVESTED (Rs.)	PERIOD OF DEPOSIT	RATE OF INTEREST(%)	DATE MATURITY / REDEMPTION	AMOUNT DUE ON MATURITY (Rs.)
A- SHORT TERM DEPOSIT WITH BANK OF BARODA						
21860300022595	01.03.2013	1,22,09,252.00	1 Year	9.31%	01.03.2014	1,33,86,237.00
TOTAL OF SCHEDULE -3	-	**1,22,09,252.00**				**1,33,86,237.00**

INDIAN PHARMACOPOEIA COMMISSION
Ministry of Health and Welfare
General Provident Fund

SCHEDULE - 4

Significant accounting policies and Notes to accounts.
(Forming part of the Financial Statements for the year ended 31st March 2013)

A. SIGNIFICANT ACCOUNTING POLICIES

1.Method of accounting:

The accounts have been prepared under the Historical cost convention on accrual basis.

2.Revenue Recognition:

The Revenue has been recognized on accrual basis.

3.Fixed Assets:

There are no fixed assets.

4.Investments:

Investments are stated at cost and are held in the name of the "Indian Pharmacopoeia Commission General Provident Fund" (herein after referred to as "IPC – GPF").

B. <u>NOTES TO ACCOUNTS</u>

1. "IPC – GPF" is not yet registered with the desired Govt. Authorities.

2. The investments of "IPC-GPF" have been invested in Fixed Deposit with Nationalized bank.

3. The accounting standards issued by ICAI wherever applicable have been complied to the extent possible.

4. The previous year's figures have been regrouped/reclassified/rearranged, wherever necessary to confirm to the current period presentation.

For P A R Y & CO. **FOR INDIAN PHARMACOPOEIA COMMISSION**

Chartered Accountants
(FR No. 007288C)

Dr. G.N. Singh
(Secretary-cum -Scientific Director)

Yogesh Malik
F.C.A, D.I.S.A (ICA)
Sr. Partner
(M. No. 074635)

Chandan Kumar
(Finance & Accounts Officer)

I.J.S. Oberoi
(Administrative Officer)(i/c)

Place: Ghaziabad
Date: 02.09.2013